0001171843-22-003220.txt : 20220504 0001171843-22-003220.hdr.sgml : 20220504 20220504161707 ACCESSION NUMBER: 0001171843-22-003220 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 70 CONFORMED PERIOD OF REPORT: 20220331 FILED AS OF DATE: 20220504 DATE AS OF CHANGE: 20220504 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HARVARD BIOSCIENCE INC CENTRAL INDEX KEY: 0001123494 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 043306140 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33957 FILM NUMBER: 22891729 BUSINESS ADDRESS: STREET 1: 84 OCTOBER HILL RD CITY: HOLLISTON STATE: MA ZIP: 01746 BUSINESS PHONE: 5088938999 MAIL ADDRESS: STREET 1: 84 OCTOBER HILL ROAD CITY: HOLLISTON STATE: MA ZIP: 01746 10-Q 1 hboi20220331_10q.htm FORM 10-Q hboi20220331_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

FORM 10-Q

☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended March 31, 2022

☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from_____to _____

Commission file number 001-33957

HARVARD BIOSCIENCE, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware 04-3306140

(State or other jurisdiction of (I.R.S. Employer

Incorporation or organization) Identification No.)

84 October Hill Road, Holliston, Massachusetts 01746

(Address of Principal Executive Offices, including zip code)

(508) 893-8999

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.01 par value	HBIO	The Nasdaq Global Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S- T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☒
Non-accelerated filer ☐	Smaller reporting company ☐
	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of April 29, 2022, there were 41,241,449 shares of the registrant’s common stock issued and outstanding.

Table of Contents

HARVARD BIOSCIENCE, INC.

FORM 10-Q

INDEX

	Page

PART I - FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements (unaudited)	3

Consolidated Balance Sheets	3

Consolidated Statements of Operations	4

Consolidated Statements of Comprehensive Loss	5

Consolidated Statements of Stockholders' Equity	6

Consolidated Statements of Cash Flows	7

Notes to Unaudited Consolidated Financial Statements	8

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	16

Item 3. Quantitative and Qualitative Disclosures about Market Risk	20

Item 4. Controls and Procedures	20

PART II - OTHER INFORMATION

Item 1. Legal Proceedings	21

Item1A. Risk Factors	21

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.	21

Item 3. Default Upon Senior Securities	21

Item 4. Mine Safety Disclosures	21

Item 5. Other Information	21

Item 6. Exhibits	21

SIGNATURES	22

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements.

HARVARD BIOSCIENCE, INC.

CONSOLIDATED BALANCE SHEETS

(Unaudited, in thousands, except share and per share data)

	March 31,			December 31,
	2022			2021
Assets
Current assets:
Cash and cash equivalents	$	5,433		$	7,821
Accounts receivable, net		20,274			21,834
Inventories		28,711			27,587
Other current assets		5,030			4,341
Total current assets		59,448			61,583
Property, plant and equipment, net		3,499			3,415
Operating lease right-of-use assets		6,605			6,897
Goodwill		57,356			57,689
Intangible assets, net		25,878			27,385
Other long-term assets		5,258			5,375
Total assets	$	158,044		$	162,344
Liabilities and Stockholders' Equity
Current liabilities:
Current portion of long-term debt	$	2,720		$	3,235
Current portion of operating lease liabilities		2,151			2,142
Accounts payable		6,218			4,911
Deferred revenue		3,956			4,266
Other current liabilities		12,181			10,762
Total current liabilities		27,226			25,316
Long-term debt, net		46,244			45,095
Deferred tax liability		1,442			1,558
Operating lease liabilities		6,159			6,488
Other long-term liabilities		598			486
Total liabilities		81,669			78,943
Commitments and contingencies - Note 12
Stockholders' equity:
Preferred stock, par value $0.01 per share, 5,000,000 shares authorized		-			-
Common stock, par value $0.01 per share, 80,000,000 shares authorized: 41,241,449 shares issued and outstanding at March 31, 2022; 41,142,876 shares issued and outstanding at December 31, 2021		452			452
Additional paid-in-capital		226,203			225,650
Accumulated deficit		(139,554	)		(132,674	)
Accumulated other comprehensive loss		(10,726	)		(10,027	)
Total stockholders' equity		76,375			83,401
Total liabilities and stockholders' equity	$	158,044		$	162,344

See accompanying notes to condensed consolidated financial statements.

Table of Contents

HARVARD BIOSCIENCE, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited, in thousands, except per share data)

	Three Months Ended March 31,
	2022			2021
Revenues	$	28,778		$	26,989
Cost of revenues		12,601			11,558
Gross profit		16,177			15,431

Sales and marketing expenses		6,687			5,386
General and administrative expenses		6,325			6,333
Research and development expenses		3,220			2,487
Amortization of intangible assets		1,466			1,464
Settlement of litigation - Note 13		5,191			-
Total operating expenses		22,889			15,670

Operating loss		(6,712	)		(239	)

Other (expense) income:
Interest expense		(384	)		(411	)
Other income (expense), net		78			(34	)
Total other expense		(306	)		(445	)

Loss before income taxes		(7,018	)		(684	)
Income tax benefit		(138	)		(15	)
Net loss	$	(6,880	)	$	(669	)

Loss per share:
Basic and diluted loss per common share	$	(0.17	)	$	(0.02	)

Weighted-average common shares:
Basic and diluted		41,219			39,787

See accompanying notes to condensed consolidated financial statements.

Table of Contents

HARVARD BIOSCIENCE, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(Unaudited, in thousands)

	Three Months Ended March 31,
	2022			2021

Net loss	$	(6,880	)	$	(669	)
Other comprehensive loss:
Foreign currency translation adjustments		(699	)		(1,325	)
Comprehensive loss	$	(7,579	)	$	(1,994	)

See accompanying notes to condensed consolidated financial statements.

Table of Contents

HARVARD BIOSCIENCE, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

(Unaudited, in thousands)

												Accumulated
	*Number*					*Additional*						*Other*						*Total*
	*of Shares*			*Common*		*Paid-in*			*Accumulated*			*Comprehensive*			*Treasury*			*Stockholders*’
	*Issued*			*Stock*		*Capital*			*Deficit*			*Loss*			*Stock*			*Equity*
Balance at December 31, 2021		41,143		$	452	$	225,650		$	(132,674	)	$	(10,027	)	$	-		$	83,401
Stock option exercises		11			-		31			-			-			-			31
Vesting of restricted stock units		151			-		-			-			-			-			-
Shares withheld for taxes		(64	)		-		(501	)		-			-			-			(501	)
Stock-based compensation expense		-			-		1,023			-			-			-			1,023
Net loss		-			-		-			(6,880	)		-			-			(6,880	)
Other comprehensive loss		-			-		-			-			(699	)		-			(699	)
Balance at March 31, 2022		41,241		$	452	$	226,203		$	(139,554	)	$	(10,726	)	$	-		$	76,375

Balance at December 31, 2020		47,153		$	444	$	232,357		$	(132,386	)	$	(13,066	)	$	(10,668	)	$	76,681
Stock option exercises		311			4		1,920			-			-			-			1,924
Vesting of restricted stock units		340			-		-			-			-			-			-
Shares withheld for taxes		(108	)		-		(464	)		-			-			-			(464	)
Stock-based compensation expense		-			-		968			-			-			-			968
Net loss		-			-		-			(669	)		-			-			(669	)
Other comprehensive loss		-			-		-			-			(1,325	)		-			(1,325	)
Balance at March 31, 2021		47,696		$	448	$	234,781		$	(133,055	)	$	(14,391	)	$	(10,668	)	$	77,115

See accompanying notes to condensed consolidated financial statements.

Table of Contents

HARVARD BIOSCIENCE, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited, in thousands)

	Three Months Ended March 31,
	2022			2021
Cash flows from operating activities:
Net loss	$	(6,880	)	$	(669	)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation		382			445
Amortization of intangible assets		1,466			1,464
Amortization of deferred financing costs		70			70
Stock-based compensation expense		1,023			968
Deferred income taxes and other		(123	)		(53	)
Changes in operating assets and liabilities:
Accounts receivable		1,506			584
Inventories		(1,308	)		(602	)
Other assets		(466	)		(94	)
Accounts payable and accrued expenses		2,729			(245	)
Deferred revenue		(300	)		(135	)
Other liabilities		(85	)		(696	)
Net cash (used in) provided by operating activities		(1,986	)		1,037

Cash flows from investing activities:
Additions to property, plant and equipment		(471	)		(151	)
Additions to intangible assets		-			(150	)
Net cash used in investing activities		(471	)		(301	)

Cash flows from financing activities:
Borrowing from revolving line of credit		1,500			-
Repayment of revolving line of credit		-			(4,000	)
Repayment of term debt		(936	)		(500	)
Debt issuance costs		-			(101	)
Proceeds from exercise of stock options		31			1,924
Taxes paid related to net share settlement of equity awards		(501	)		(464	)
Net cash provided by (used in) financing activities		94			(3,141	)

Effect of exchange rate changes on cash		(25	)		(97	)
Decrease in cash and cash equivalents		(2,388	)		(2,502	)
Cash and cash equivalents at beginning of period		7,821			8,317
Cash and cash equivalents at end of period	$	5,433		$	5,815

Supplemental disclosures of cash flow information:
Cash paid for interest	$	383		$	458
Cash paid (received) for income taxes, net of refunds	$	107		$	(113	)

See accompanying notes to condensed consolidated financial statements.

Table of Contents

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

1.	Basis of Presentation and Summary of Significant Accounting Policies, and Risks and Uncertainties

Basis of Presentation and Summary of Significant Accounting Policies

The unaudited consolidated financial statements of Harvard Bioscience, Inc. and its wholly-owned subsidiaries (collectively, “Harvard Bioscience” or the “Company”) as of March 31, 2022 and for the three months ended March 31, 2022 and 2021, have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. The December 31, 2021, consolidated balance sheet was derived from audited financial statements but does not include all disclosures required by U.S. GAAP. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021.

In the opinion of management, all adjustments, which include normal recurring adjustments necessary to present a fair statement of financial position as of March 31, 2022, results of operations and comprehensive loss and cash flows for the three months ended March 31, 2022 and 2021, as applicable, have been made. The results of operations for the three months ended March 31, 2022, are not necessarily indicative of the operating results for the full fiscal year or any future periods.

The accounting policies underlying the accompanying unaudited consolidated financial statements are set forth in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. There have been no material changes in the Company’s significant accounting policies during the three months ended March 31, 2022.

Risks and Uncertainties

On March 11, 2020, the World Health Organization declared the outbreak of a novel coronavirus (COVID-19) as a pandemic. The COVID-19 pandemic has had a negative impact on the Company’s operations to date and the future impacts of the pandemic and any resulting economic impact are largely unknown and rapidly evolving. Since the global outbreak of COVID-19, many customers, particularly academic research institutions, have reduced laboratory work which has negatively impacted, and will continue to negatively impact, the Company’s sales. Also, countries world-wide continue to issue COVID-19 related policies in an attempt to control the pandemic. In particular, during the beginning of 2022, China implemented area-wide shutdowns in order to control the spread of COVID-19. To ensure business continuity while maintaining a safe environment for employees aligned with guidance from government and health organizations, the Company transitioned a significant portion of its workforce to work-from-home while implementing social distancing requirements and other measures to allow manufacturing and other personnel essential to production to continue work within the Company's facilities. Business travel was significantly reduced during this period. While a portion of the workforce has returned to in-office work and travel is less restricted, the Company continued to have restrictions which represent disruptions that can impact productivity including sales and marketing activities.

The global supply chain has experienced significant disruptions due to electronic component and labor shortages and other macroeconomic factors which have emerged since the onset of COVID-19, leading to increased cost of freight, purchased materials, and manufacturing labor costs, while also delaying customer shipments. Accordingly, these conditions in addition to the overall impact on the global economy have negatively impacted results of operations and cash flows.

2.	Recently Issued Accounting Pronouncements

Accounting Pronouncements to be Adopted

In November 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2021-10, Government Assistance (Topic 832), Disclosures by Business Entities About Government Assistance, which requires entities to provide disclosures on material government assistance transactions for annual reporting periods. The disclosures include information around the nature of the assistance, the related accounting policies used to account for government assistance, the effect of government assistance on the entity’s financial statements, and any significant terms and conditions of the agreements, including commitments and contingencies. The new standard impacts footnote disclosures and is effective for the Company’s December 31, 2022 annual financial statements. The Company is currently evaluating the potential impact of adopting ASU 2021-10 will have on its consolidated financial statements.

Table of Contents

In January 2017, the FASB issued ASU 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment (ASU 2017-04), which eliminates the performance of Step 2 from the goodwill impairment test. In performing its annual or interim impairment testing, an entity will instead compare the fair value of the reporting unit with its carrying amount and recognize any impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value. Additionally, an entity should consider income tax effects from any tax-deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss. ASU 2017-04 is effective for the Company for fiscal years beginning after December 15, 2022. The Company is currently evaluating the potential impact that adopting ASU 2017-04 will have on its consolidated financial statements.

In September 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (ASU 2016-13), which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses rather than incurred losses to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. The FASB issued several ASUs after ASU 2016-13 to clarify implementation guidance and to provide transition relief for certain entities. ASU 2016-13 is effective for the Company for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company is evaluating the impact that adopting ASU 2016-13 and related amendments will have on its consolidated financial statements.

3.	Goodwill and Intangible Assets

Goodwill

The change in the carrying amount of goodwill for the three months ended March 31, 2022, were as follows:

(in thousands)
Carrying amount at December 31, 2021	$	57,689
Effect of change in currency translation		(333	)
Carrying amount at March 31, 2022	$	57,356

Intangible Assets

Identifiable intangible assets at March 31, 2022 and December 31, 2021 consist of the following:

			March 31, 2022							December 31, 2021
(in thousands)	Average				Accumulated							Accumulated
Amortizable intangible assets:	Life*		Gross		Amortization			Net		Gross		Amortization			Net
Distribution agreements/customer relationships		7.7	$	17,594	$	(8,938	)	$	8,656	$	17,689	$	(8,675	)	$	9,014
Existing technology		3.9		38,611		(24,786	)		13,825		38,707		(23,962	)		14,745
Trade names and patents		4.2		8,467		(5,304	)		3,163		8,496		(5,108	)		3,388
Total amortizable intangible assets			$	64,672	$	(39,028	)	$	25,644	$	64,892	$	(37,745	)	$	27,147
Indefinite-lived intangible assets:									234							238
Total intangible assets								$	25,878						$	27,385

* Weighted average life in years as of March 31, 2022

Intangible asset amortization expense was $1.5 million for each the three months ended March 31, 2022 and 2021. Estimated amortization expense of existing amortizable intangible assets for each of the five succeeding years and thereafter as of March 31, 2022, is as follows:

	Amortization
Year Ending December 31,	Expense
(in thousands)
2022 (remainder of year)	$	4,366
2023		5,728
2024		5,427
2025		4,109
2026		2,368
Thereafter		3,646
Total	$	25,644

Table of Contents

4.	Balance Sheet Information

The following tables provide details of selected balance sheet items as of the periods indicated:

*Inventories:*	March 31,		December 31,
(in thousands)	2022		2021
Finished goods	$	6,798	$	5,646
Work in process		3,439		3,410
Raw materials		18,474		18,531
Total	$	28,711	$	27,587

*Other Current Liabilities:*	March 31,		December 31,
(in thousands)	2022		2021
Compensation	$	2,878	$	6,048
Professional fees		396		480
Warranty costs		242		240
Customer related costs		2,058		2,265
Settlement of litigation		4,814		-
Accrued income taxes		141		224
Other		1,653		1,505
Total	$	12,181	$	10,762

5.	Restructuring and Other Exit Costs

On an ongoing basis, the Company reviews the global economy, the healthcare industry, and the markets in which it competes to identify operational efficiencies, enhance commercial capabilities, and align its cost base and infrastructure with customer needs and its strategic plans. In order to realize these opportunities, the Company undertakes restructuring-type activities from time to time to transform its business. A portion of these transformation activities are considered restructuring costs under ASC 420 – Exit or Disposal Cost Obligations and are discussed below.

During 2019, the Company initiated a restructuring program to improve operational efficiency and reduce costs which entailed consolidating and downsizing several sites and headcount reductions in Europe and North America. This program was completed in 2021. Restructuring costs under this program were $0.6 million for the three months ended March 31, 2021, substantially all of which have been included as a component of general and administrative expenses.

6.	Related Party Transactions

In connection with the 2014 acquisitions of Multi Channel Systems MCS GmbH (“MCS”), the Company entered into a facility lease agreement with the former principal owner of MCS who became an employee of the Company at the time of the acquisition and subsequently retired in 2021. The MCS agreement expires on December 31, 2024. Pursuant to this lease agreement, the Company made rent payments of approximately $0.1 million for each of the three months ended March 31, 2022 and 2021.

Table of Contents

7.	Leases

The Company has noncancelable operating leases for offices, manufacturing facilities, warehouse space, automobiles and equipment expiring at various dates through 2030.

The components of lease expense for the three months ended March 31, 2022 and 2021, are as follows:

	Three Months Ended March 31,
(in thousands)	2022			2021
Operating lease cost	$	504		$	517
Short-term lease cost		64			46
Sublease income		(25	)		(25	)
Total lease cost	$	543		$	538

Supplemental cash flow information related to the Company's operating leases was as follows:

	Three Months Ended March 31,
(in thousands)	2022		2021
Cash paid for amounts included in the measurement of lease liabilities:	$	594	$	611
Right-of-use assets obtained in exchange for lease obligations:	$	39	$	-

Supplemental balance sheet information related to the Company's operating leases was as follows:

	March 31,			December 31,
(in thousands)	2022			2021
Operating lease right-of-use assets	$	6,605		$	6,897

Current portion, operating lease liabilities	$	2,151		$	2,142
Operating lease liabilities, long-term		6,159			6,488
Total operating lease liabilities	$	8,310		$	8,630

Weighted average remaining lease term (years)		6.5			6.7
Weighted average discount rate		9.3	%		9.3	%

Future minimum lease payments for operating leases for each twelve-month period subsequent to March 31, 2022, are as follows:

Year Ending December 31,
(in thousands)
2022 (remainder of year)	$	1,611
2023		2,133
2024		1,765
2025		1,019
2026		980
Thereafter		3,871
Total lease payments		11,379
Less imputed interest		(3,069	)
Total operating lease liabilities	$	8,310

Table of Contents

8.	Capital Stock and Stock-Based Compensation

Stock-Based Payment Awards

Stock-based awards consist of stock options, time-based restricted stock units (“RSUs”), performance-based RSU’s and shares issued under the Company’s employee stock purchase plan. Activity under the Company’s equity incentive plans for the three months ended March 31, 2022, was as follows:

				Weighted
	*Stock*			*Average*		*Time-Based*					*Performance-*
	*Options*			*Exercise*		*RSUs*			*Grant Date*		*Based RSUs*		*Grant Date*
	*Outstanding*			*Price*		*Outstanding*			*Fair Value*		*Outstanding*		*Fair Value*
Balance at December 31, 2021		1,404,816		$	3.10		1,141,164		$	3.57		860,155	$	3.13
Granted		-			-		518,163			5.52		205,122		5.92
Exercised		(10,987	)		2.78		-			-		-		-
Vested (RSUs)		-			-		(151,185	)		2.30		-		-
Cancelled/Forfeited		(3,126	)		3.79		(12,917	)		3.07		-		-
Balance at March 31, 2022		1,390,703		$	3.10		1,495,225		$	4.37		1,065,277	$	3.67

Stock-based compensation expense for the three months ended March 31, 2022 and 2021, was allocated as follows:

	Three Months Ended March 31,
(in thousands)	2022		2021
Cost of revenues	$	36	$	20
Sales and marketing expenses		154		93
General and administrative expenses		791		834
Research and development expenses		42		21
Total stock-based compensation expenses	$	1,023	$	968

As of March 31, 2022, the total compensation costs related to unvested awards not yet recognized is $8.2 million and the weighted average period over which it is expected to be recognized is approximately 2.2 years. The Company did not capitalize any stock-based compensation.

The weighted average estimated fair value of the performance-based RSUs that were granted during the three months ended March 31, 2022 was $5.92 per unit. The following assumptions were used to estimate the fair value of the performance-based RSUs granted during the three months ended March 31, 2022 using a Monte-Carlo valuation simulation:

	2022
Volatility		65.1	%
Risk-free interest rate		1.4	%
Correlation coefficient		38.5	%
Dividend yield		-	%

Earnings (Loss) Per Share

Basic earnings (loss) per share (EPS) is calculated by dividing net income (loss) by the number of weighted average shares of common stock outstanding during the period. The calculation of diluted earnings per share assumes conversion of stock options, time-based RSUs, and performance-based RSUs into common stock using the treasury method. The weighted average number of shares used to compute basic and diluted earnings per share consists of the following:

	Three Months Ended March 31,
(in thousands)	2022		2021
Basic		41,219		39,787
Dilutive effect of equity awards		-		-
Diluted		41,219		39,787

For the three months ended March 31, 2022, and 2021, the Company excluded from the calculations of diluted earnings per share approximately 3.5 million shares and 4.5 million shares, respectively, of weighted average shares of underlying stock-based awards as the impact of including these potential shares would be anti-dilutive.

Table of Contents

9.	Long-Term Debt

As of March 31, 2022 and December 31, 2021, the Company’s borrowings were comprised of:

	March 31,			December 31,
(in thousands)	2022			2021
Long-term debt:
Term loan	$	37,064		$	38,000
Revolving line		12,950			11,450
Less unamortized deferred financing costs		(1,050	)		(1,120	)
Total debt		48,964			48,330
Current portion of long-term debt		(3,000	)		(3,515	)
Current unamortized deferred financing costs		280			280
Long-term debt	$	46,244		$	45,095

On December 22, 2020, the Company entered into a Credit Agreement (the “Credit Agreement”) with Citizens Bank, N.A., Wells Fargo Bank, National Association, and Silicon Valley Bank (together, the “Lenders”). The Credit Agreement provides for a term loan of $40.0 million and a $25.0 million senior revolving credit facility (including a $10.0 million sub-facility for the issuance of letters of credit and a $10.0 million swingline loan sub facility) (collectively, the “Credit Facility”). The Company’s obligations under the Credit Agreement are guaranteed by certain of the Company’s direct, domestic wholly-owned subsidiaries; none of the Company’s direct or indirect foreign subsidiaries has guaranteed the Credit Facility. The Company’s obligations under the Credit Agreement are secured by substantially all of the assets of Harvard Bioscience, Inc., and each guarantor (including all or a portion of the equity interests in certain of the Company’s domestic and foreign subsidiaries). The Credit Facility matures on December 22, 2025. Issuance costs of $1.4 million are amortized over the contractual term to maturity date on a straight-line basis, which approximates the effective interest method. Available and unused borrowing capacity under the revolving line of credit was $6.8 million as of March 31, 2022. Total revolver borrowing capacity is limited by the Maximum Leverage ratio as defined under the Credit Agreement. The Credit Facility replaced the Company’s prior credit facility, which was repaid with borrowings under the Credit Facility.

Borrowings under the Credit Facility will, at the option of the Company, bear interest at either (i) a rate per annum based on LIBOR for an interest period of one, two, three or six months, plus an applicable interest rate margin determined as provided in the Credit Agreement (a “LIBOR Loan”), or (ii) an alternative base rate plus an applicable interest rate margin, each as determined as provided in the Credit Agreement (an “ABR Loan”). LIBOR interest under the Credit Agreement is subject to applicable market rates and a floor of 0.50 %. The alternative base rate is based on the Citizens Bank prime rate or the federal funds effective rate of the Federal Reserve Bank of New York and is subject to a floor of 1.0%. The applicable interest rate margin varies from 2.0% per annum to 3.25% per annum for LIBOR Loans, and from 1.5% per annum to 3.0% per annum for ABR Loans, in each case depending on the Company’s consolidated leverage ratio and is determined in accordance with a pricing grid set forth in the Credit Agreement. The LIBOR index is expected to be phased out over time and the terms of the Credit Agreement allow for a replacement when that occurs. Interest on LIBOR Loans is payable in arrears on the last day of each applicable interest period, and interest on ABR Loans is payable in arrears at the end of each calendar quarter. There are no prepayment penalties in the event the Company elects to prepay and terminate the Credit Facility prior to its scheduled maturity date, subject to LIBOR breakage and redeployment costs in certain circumstances.

As of March 31, 2022, the weighted average interest rate on the Credit Agreement borrowings was 3.4%. The effective interest rate for the three months ended March 31, 2022 and 2021, was 3.1% and 3.3%, respectively. The carrying value of the debt approximates fair value because the interest rate under the obligation approximates market rates of interest available to the Company for similar instruments.

Commencing on March 31, 2021, the outstanding term loans amortizes in quarterly installments of $0.5 million per quarter on such date and during each of the next three quarters thereafter, $0.75 million per quarter during the next eight quarters thereafter and $1.0 million per quarter thereafter, with a balloon payment at maturity. Furthermore, within ninety days after the end of the Company’s fiscal year ended December 31, 2021, and for each fiscal year thereafter, the term loans may be permanently reduced pursuant to certain mandatory prepayment events including an annual “excess cash flow sweep” of 50% of the consolidated excess cash flow, as defined in the agreement; provided that, in any fiscal year, any voluntary prepayments of the term loans shall be credited against the Company’s “excess cash flow” prepayment obligations on a dollar-for-dollar basis for such fiscal year. Amounts outstanding under the revolving credit facility can be repaid at any time but are due in full at maturity. The Company made an excess cash flow sweep payment of $0.2 million during the three months ended March 31, 2022.

The Credit Agreement includes customary affirmative, negative, and financial covenants binding on the Company. The negative covenants limit the ability of the Company, among other things, to incur debt, incur liens, make investments, sell assets and pay dividends on its capital stock. The financial covenants include a maximum consolidated net leverage ratio and a minimum consolidated fixed charge coverage ratio. The Credit Agreement also includes customary events of default.

On April 28, 2022, the Company entered into an amendment to the Credit Agreement and Pledge and Security Agreement (the “Amendment”), among the Company, the Lenders, and Citizens Bank, N.A., as the administrative agent (the “Administrative Agent”). Pursuant to the Amendment, the Lenders and the Administrative Agent have agreed, among other things, (i) to modify the financial covenant relating to the consolidated net leverage ratio and (ii) to consent to the Settlement described in Note 13- “Subsequent Events”. In consideration for the Amendment, the Company paid a fee of $0.2 million to the Lenders and the Administrative Agent. The Company was in compliance with the covenants of the Credit Agreement, as amended by the Amendment, as of March 31, 2022.

Table of Contents

10.

Revenues

The following tables represent a disaggregation of revenue from contracts with customers for the three months ended March 31, 2022 and 2021:

	Three Months Ended March 31,
(in thousands)	2022		2021
Instruments, equipment, software and accessories	$	27,538	$	25,827
Service, maintenance and warranty contracts		1,240		1,162
Total revenues	$	28,778	$	26,989

The following tables represent a disaggregation of revenue by geographic destination for the three months ended March 31, 2022 and 2021:

	Three Months Ended March 31,
(in thousands)	2022		2021
United States	$	12,239	$	11,177
Europe		7,823		8,589
Asia		6,733		5,538
Rest of the world		1,983		1,685
Total revenues	$	28,778	$	26,989

Deferred revenue

The following tables provide details of deferred revenue as of the periods indicated:

	March 31,		December 31,
(in thousands)	2022		2021
Service contracts	$	1,995	$	1,976
Customer advances		1,961		2,290
Total deferred revenue	$	3,956	$	4,266

During the three months ended March 31, 2022 and 2021, the Company recognized revenue of $0.7 million and $1.2 million from contract liabilities existing at December 31, 2021 and 2020, respectively.

Allowance for Doubtful Accounts

Allowance for doubtful accounts is based on the Company’s assessment of the collectability of accounts receivable. Activity in the allowance for doubtful accounts is as follows:

	Three Months Ended March 31,
(in thousands)	2022			2021
Balance, beginning of period	$	136		$	227
Bad debt (credit) expense		(6	)		5
Charge-offs and other		6			22
Balance, end of period	$	136		$	254

Concentrations

No customer accounted for more than 10% of revenues for the three months ended March 31, 2022 and 2021. At March 31, 2022 and December 21, 2021, no customer accounted for more than 10% of net accounts receivable.

11.

Income Tax

Income tax benefit was $0.1 million for the three months ended March 31, 2022 and was less than $0.1 million for the three months ended March 31, 2021. The effective tax rates for the three months ended March 31, 2022 and 2021, were 2.0% and 2.2%, respectively.

The difference between the Company’s effective tax rates in 2022 and 2021 compared to the U.S. statutory tax rate of 21% is primarily due to changes in valuation allowances associated with the Company’s assessment of the likelihood of the recoverability of deferred tax assets. The Company currently has valuation allowances against substantially all of its net operating loss carryforwards and tax credit carryforwards.

Table of Contents

12.

Commitments and Contingent Liabilities

On April 14, 2017, representatives for the estate of an individual plaintiff filed a wrongful death complaint with the Suffolk Superior Court, in the County of Suffolk, Massachusetts, against the Company and other defendants, including Biostage, Inc. (f/k/a Harvard Apparatus Regenerative Technology, Inc.) (“Biostage”), a former subsidiary of the Company that was spun off in 2013, as well as another third party. The complaint seeks payment for an unspecified amount of damages and alleges that the plaintiff sustained terminal injuries allegedly caused by products, including one synthetic trachea scaffold and two bioreactors, provided by certain of the named defendants and utilized in connection with surgeries performed by third parties in Europe in 2012 and 2013.

On April 28, 2022, the Company and Biostage executed a settlement with the plaintiffs (the “Settlement”) which resolves all claims relating to the litigation. The settlement is described in Note 13 – “Subsequent Events – Litigation Settlement”.

The Company is involved in various other claims and legal proceedings arising in the ordinary course of business. After consultation with legal counsel, the Company has determined that the ultimate disposition of such proceedings is not likely to have a material adverse effect on its business, financial condition, results of operations or cash flows. Although unfavorable outcomes in the proceedings are possible, the Company has not accrued for loss contingencies relating to any such matters as they are not considered to be probable and reasonably estimable. If one or more of these matters are resolved in a manner adverse to the Company, the impact on the Company’s business, financial condition, results of operations and cash flows could be material.

13.

Subsequent Events

Litigation Settlement

On April 27, 2022, the Company and Biostage executed a settlement with the plaintiffs and Biostage’s products liability insurance carriers (the “Settlement”), which resolves with prejudice all claims relating to the litigation, including outstanding lawsuits with the plaintiffs and one of the insurance carriers. The Settlement was entered into solely by way of compromise and settlement and is not in any way an admission of liability or fault by the Company or Biostage. The Company has accrued $5.2 million of costs related to the legal fees and the Settlement as of March 31, 2022. Biostage is required to indemnify the Company for all losses and expenses, including legal expenses, the Company incurs in connection with the litigation and the Settlement. The Company and Biostage have agreed in principle that, in satisfaction of $4.0 million of its total indemnification obligations, Biostage will issue senior convertible preferred stock to the Company. The issuance of such preferred stock, and the terms thereof, are subject to the negotiation and execution of definitive documents. Due to Biostage’s current financial condition, there is uncertainty as to whether Biostage’s indemnification obligation together with the value, if any, of such preferred stock will offset the amounts the Company has incurred in connection with the litigation and Settlement, if at all. Accordingly, as of March 31, 2022, the Company has fully reserved any receivables from Biostage and the financial results only reflect expected losses to be paid by the Company.

Credit Agreement Amendment

On April 28, 2022, the Company entered into an amendment to the Credit Agreement and Pledge and Security Agreement (the “Amendment”), among the Company, the Lenders, and Citizens Bank, N.A., as the administrative agent (the “Administrative Agent”). Pursuant to the Amendment, the Lenders and the Administrative Agent have agreed, among other things, (i) to modify the financial covenant relating to the consolidated net leverage ratio and (ii) to consent to the Settlement described above. In consideration for the Amendment, the Company paid a fee of $0.2 million to the Lenders and the Administrative Agent.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Forward-Looking Statements

This Quarterly Report on Form 10-Q contains statements that are not statements of historical fact and are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”). The forward-looking statements are principally, but not exclusively, contained in “Item 2: Management’s Discussion and Analysis of Financial Condition and Results of Operations.” These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about management’s confidence or expectations, and our plans, objectives, expectations, and intentions that are not historical facts. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “seek,” “expects,” “plans,” “aim,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “intends,” “think,” “potential,” “objectives,” “optimistic,” “strategy,” “goals,” “sees,” “new,” “guidance,” “future,” “continue,” “drive,” “growth,” “long-term,” “projects,” “develop,” “possible,” “emerging,” “opportunity,” “pursue” and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We discuss many of these risks in detail in our Annual Report on Form 10-K for year ended December 31, 2021. You should carefully review all of these factors, as well as other risks described in our public filings, and you should be aware that there may be other factors, including factors of which we are not currently aware, that could cause these differences. Also, these forward-looking statements represent our estimates and assumptions only as of the date of this report. We may not update these forward-looking statements, even though our situation may change in the future, unless we have obligations under the federal securities laws to update and disclose material developments related to previously disclosed information. Harvard Bioscience, Inc. is referred to herein as “we,” “our,” “us,” and “the Company.”

Recent Developments

COVID-19

On March 11, 2020, the World Health Organization declared the outbreak of a novel coronavirus (COVID-19) as a pandemic. The COVID-19 pandemic has had a negative impact on our operations to date and the future impacts of the pandemic and any resulting economic impact remain unknown and continuously evolving. Since the global outbreak of COVID-19, many customers, particularly academic research institutions, reduced laboratory work which has negatively impacted, and will continue to negatively impact, our sales. Also, countries world-wide continue to issue COVID-19 related policies in an attempt to control the pandemic. In particular, during the beginning of 2022, China implemented area-wide shutdowns in order to control the spread of COVID-19. Additionally, to ensure business continuity while maintaining a safe environment for employees aligned with guidance from government and health organizations, we transitioned a significant portion of our workforce to work-from-home while implementing social distancing requirements and other measures to allow manufacturing and other personnel essential to production to continue work within our facilities. Business travel was significantly reduced during this period. While a portion of the workforce has returned to in-office work and travel is less restricted, we continue to have restrictions which represent disruptions that can impact productivity including sales and marketing activities.

The global supply chain has experienced significant disruptions due to electronic component and labor shortages and other macroeconomic factors which have emerged since the onset of COVID-19, leading to increased cost of freight, purchased materials and manufacturing labor costs, while also delaying customer shipments. We believe these supply chain trends will continue through the rest of 2022. These conditions in addition to the overall impact on the global economy have negatively impacted our results of operations and cash flows.

If business interruptions resulting from COVID-19 were to be prolonged or expanded in scope, our business, financial condition, results of operations and cash flows would be negatively impacted. We will continue to actively monitor this situation and will implement actions necessary to maintain business continuity.

Table of Contents

Selected Results of Operations

Three months ended March 31, 2022 compared to three months ended March 31, 2021.

	Three Months Ended March 31,
(dollars in thousands)	2022			% of revenue			2021			% of revenue
Revenues	$	28,778					$	26,989
Gross profit		16,177			56.2	%		15,431			57.2	%
Sales and marketing expenses		6,687			23.2	%		5,386			20.0	%
General and administrative expenses		6,325			22.0	%		6,333			23.5	%
Research and development expenses		3,220			11.2	%		2,487			9.2	%
Amortization of intangible assets		1,466			5.1	%		1,464			5.4	%
Settlement of litigation		5,191			18.0	%		-			-
Interest expense		384			1.3	%		411			1.5	%
Income tax benefit		(138	)		-0.5	%		(15	)		-0.1	%

Revenue

Revenues for the three months ended March 31, 2022, were $28.8 million, an increase of approximately $1.8 million, or 6.6%, compared to revenues of $27.0 million for the three months ended March 31, 2021. Revenues increased due to improved sales of products from our preclinical product family associated with improved sales processes as well as improvements in order fulfillment processes which reduce order backlog. These improvements were offset by lower orders from customers in Asia than the prior year due to COVID lockdowns in China in 2022 which delayed orders. We expect sales to China customers to remain at reduced levels until lockdown conditions are removed.

Gross profit

Gross profit increased $0.7 million, or 4.8%, to $16.2 million for the three months ended March 31, 2022, compared with $15.4 million for the three months ended March 31, 2021, due primarily to the increase in revenue noted. Gross margin decreased to 56.2% for the three months ended March 31, 2022, compared with 57.2% for the three months ended March 31, 2021. The decrease in gross margin was due to higher supply chain, logistics and manufacturing labor costs. The global supply chain has experienced significant disruptions due to electronic component and labor shortages and other macroeconomic factors, leading to the increased cost noted. We believe these supply chain trends will continue through the rest of 2022. These costs were partially offset by volume increases and improved product mix and pricing.

Sales and marketing expenses

Sales and marketing expenses increased $1.3 million, or 24.2%, to $6.7 million for the three months ended March 31, 2022, compared to $5.4 million during the same period in 2021. The increase was primarily due to investments in new marketing and sales support personnel and increases in travel and attendance at in-person trade shows. Travel and tradeshow costs were lower in the prior year quarter due to COVID restrictions.

General and administrative expenses

General and administrative expenses were $6.3 million for both the three months ended March 31, 2022, and March 31, 2021. General and administrative expenses for the three months ended March 31, 2022 experienced lower restructuring expenses and variable compensation which were offset by higher consulting costs associated with enterprise-level operational improvement planning.

Research and development expenses

Research and development expenses were $3.2 million for the three months ended March 31, 2022, an increase of $0.7 million, or 29.5%, compared with $2.5 million for the three months ended March 31, 2021. The increase was primarily due to costs involving investments in our preclinical product lines.

Amortization of intangible assets

Amortization of intangible asset expenses were $1.5 million for both the three months ended March 31, 2022, and March 31, 2021.

Table of Contents

Settlement of litigation

On April 27, 2022, the Company and Biostage executed a settlement with the plaintiffs and Biostage’s products liability insurance carriers (the “Settlement”), which resolves with prejudice all claims relating to the litigation, including outstanding lawsuits with the plaintiffs and one of the insurance carriers (see “Subsequent Events” – Litigation Settlement ” included in Note 13 to our Condensed Consolidated Financial Statements included in “Part I, Item 1. Financial Statement” of this report). We have accrued approximately $5.2 million of costs as of March 31, 2022, and expect to incur an additional $0.8 million of expenses as a result of legal fees and the Settlement. Biostage is required to indemnify us for all losses and expenses, including legal expenses, we incur in connection with the Settlement. We and Biostage have agreed in principle that, in satisfaction of $4.0 million of its total indemnification obligations, Biostage will issue senior convertible preferred stock to the Company. The issuance of such preferred stock, and the terms thereof, are subject to the negotiation and execution of definitive documents. Due to Biostage’s current financial condition, there is uncertainty as to whether Biostage’s indemnification obligation together with the value, if any, of such preferred stock will offset the amounts the Company has incurred in connection with the litigation and Settlement, if at all. Accordingly, as of March 31, 2022, we have fully reserved any receivables from Biostage and the financial results only reflect expected losses to be paid by us.

Interest expense

Interest expense was $0.4 million for both the three months ended March 31, 2022, and March 31, 2021.

Income tax benefit

Income tax benefit for the three months ended March 31, 2022 was $0.1 million and was less than $0.1 million for the three months ended March 31, 2021. The effective tax rates for the three months ended March 31, 2022 and 2021 were 2.0% and 2.2%, respectively The difference between our effective tax rates in 2022 and 2021 compared to the U.S. statutory tax rate of 21% is primarily due to changes in valuation allowances associated with our assessment of the likelihood of the recoverability of our deferred tax assets. We currently have valuation allowances against substantially all of our net operating loss carryforwards and tax credit carryforwards.

Liquidity and Capital Resources

Our primary sources of liquidity are cash and cash equivalents, internally generated cash flow from operations and our revolving credit facility. Our expected cash outlays relate primarily to cash payments due under our Credit Agreement described below as well as capital expenditures, payments associated with ongoing business improvement initiatives and the litigation settlement.

As of March 31, 2022, we held cash and cash equivalents of $5.4 million, compared with $7.8 million at December 31, 2021. Borrowings outstanding was $50.0 million and $49.4 million as of March 31, 2022 and December 31, 2021, respectively.

On December 22, 2020, we entered into a Credit Agreement which provides for a term loan of $40.0 million and a $25.0 million senior revolving credit facility and matures on December 22, 2025 (See Note 9 to the Condensed Consolidated Financial Statements included in “Part I, Item 1. Financial Statement” of this report). As of March 31,2022, the weighted average interest rate on our borrowings was 3.4%. Available and unused borrowing capacity under the revolving line of credit was $6.8 million as of March 31, 2022. Total revolver borrowing capacity is limited by our Maximum Leverage ratio as defined under the Credit Agreement.

On April 28, 2022, we entered into an amendment to the Credit Agreement and Pledge and Security Agreement (the “Amendment”), among the Company, the Lenders, and Citizens Bank, N.A., as the administrative agent (see Note 13- “Subsequent Events” to our Condensed Consolidated Financial Statements). We are in compliance with the covenants of the Credit Agreement, as amended by the Amendment, as of March 31, 2022.

Based on our current operating plans, we expect that our available cash, cash generated from current operations and debt capacity will be sufficient to finance current operations, any costs associated with restructuring activities and capital expenditures for at least the next 12 months. This assessment includes consideration of our best estimates of the impact of the COVID-19 pandemic on our financial results described above. Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary as a result of a number of factors.

Table of Contents

CONDENSED CONSOLIDATED CASH FLOW STATEMENTS

	Three Months Ended March 31,
(in thousands)	2022			2021
Cash (used in) provided by operating activities	$	(1,986	)	$	1,037
Cash used in investing activities		(471	)		(301	)
Cash provided by (used in) financing activities		94			(3,141	)
Effect of exchange rate changes on cash		(25	)		(97	)
Decrease in cash and cash equivalents	$	(2,388	)	$	(2,502	)

Cash (used in) provided by operating activities was $(2.0) million and $1.0 million for the three months ended March 31, 2022 and 2021, respectively. Cash flow from operations for the three months ended March 31, 2022, was lower than the same prior year period due to higher variable compensation payments as well as increases in marketing and R&D investments as discussed above.

Cash used in investing activities was $0.5 million and $0.3 million for the three months ended March 31, 2022 and 2021, respectively, primarily consisting of capital expenditures in manufacturing and information technology infrastructure.

Cash provided by (used in) financing activities was $0.1 million and $(3.1) million for the three months ended March 31, 2022 and 2021, respectively. During the three months ended March 31, 2022, we increased total debt outstanding under our credit facility by $0.6 million. This increase included $0.9 million paid under the term loan and an increase in revolver borrowings of $1.5 million. We also paid $0.5 million for taxes related to net share settlement of equity awards. During the three months ended March 31, 2021, we repaid $4.5 million of debt, which included a term loan installment payment of $0.5 million and paydown of debt under our revolving facility of $4.0 million. Net cash proceeds from the issuance of common stock associated with stock option exercises were $1.5 million during the three months ended March 31, 2021.

Impact of Foreign Currencies

Our international operations in some instances operate in a natural hedge as we sell our products in many countries and a substantial portion of our revenues, costs and expenses are denominated in foreign currencies, especially the British pound, the euro, the Canadian dollar, and the Swedish krona.

During the three months ended March 31, 2022, changes in foreign currency exchange rates resulted in an unfavorable translation effect on our consolidated revenues of approximately $0.5 million and a favorable effect on expenses of approximately $0.4 million.

The loss associated with the translation of foreign equity into U.S. dollars included as a component of comprehensive loss was $0.7 million and $1.3 million during each of the three months ended March 31, 2022 and 2021, respectively.

In addition, currency exchange rate fluctuations included as a component of net income resulted in currency (losses) gains of $(0.1) million and $0.1 million during each of the three months ended March 31, 2022 and 2021, respectively.

Critical Accounting Policies

The critical accounting policies underlying the accompanying unaudited consolidated financial statements are those set forth in Part II, Item 7 included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021.

Recently Issued Accounting Pronouncements

For information on recent accounting pronouncements impacting our business, see “Recently Issued Accounting Pronouncements” included in Note 2 to our Condensed Consolidated Financial Statements included in “Part I, Item 1. Financial Statement” of this report.

Table of Contents

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

Most of our manufacturing and testing of products occurs in our facilities in the United States, Germany, Sweden and Spain. We sell our products globally through our distributors, direct sales force, websites and catalogs. As a result, our financial results are affected by factors such as changes in foreign currency exchange rates and weak economic conditions in foreign markets. In addition, we are subject to the broad market risk that is created by the global market disruptions and uncertainties resulting from the COVID-19 pandemic.

We collect amounts representing a substantial portion of our revenues and pay amounts representing a substantial portion of our operating expenses in foreign currencies. As a result, changes in currency exchange rates from time to time may affect our operating results (see “Impact of Foreign Currencies” included in “Part I, Item 2. “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of this report). For example, we estimate that a 10% increase in foreign currency exchange rates during the three months ended March 31, 2022 as compared to the actual rates incurred, would have resulted in a favorable translation effect on our consolidated revenues of approximately $0.9 million and an unfavorable effect on expenses of approximately $0.8 million.

We are exposed to market risk from changes in interest rates primarily through our financing activities. Our Credit Facility provides for a term loan of $40.0 million and a $25.0 million senior revolving credit facility. Borrowings under the Credit Facility bear interest at variable rates (see Note 9 to our Condensed Consolidated Financial Statements included in “Part I, Item 1. Financial Statement” of this report). As of March 31, 2022, we had $50.0 million outstanding under our Credit Facility with a weighted average interest rate of 3.4%.

Assuming no other changes which would affect the margin of the interest rate, the estimated effect of interest rate fluctuations on outstanding borrowings under our Credit Facility over the next twelve months from March 31, 2022, is as follows:

(in thousands)	Interest expense increase
Interest rates increase by 1%	$	500
Interest rates increase by 2%	$	1,000

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

As of March 31, 2022, the end of the period covered by this report, our management, including our Chief Executive Officer and our Chief Financial Officer, reviewed and evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) or 15d-15(e) of the Exchange Act). Based upon management's review and evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the SEC and is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the first quarter of fiscal 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. We continue to monitor the impact of the COVID-19 pandemic and, despite many of our employees working remotely, have not experienced any changes that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on Effectiveness of Controls and Procedures

In designing and evaluating our controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud within the Company have been detected.

Table of Contents

PART II. OTHER INFORMATION

Item 1 Legal Proceedings.

The information included in Note 12 and Note 13 to the Condensed Consolidated Financial Statements (Unaudited) included in Part I, Item 1 of this quarterly report is incorporated herein by reference.

Item 1A. Risk Factors.

You should carefully consider the risk factors set forth below together with the risk factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, which could materially affect our business, financial position, or future results of operations. The risks described below and in our Annual Report on Form 10-K are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial position, or future results of operations.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

There were no unregistered sales of equity securities during the period covered by this report.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

Item 6. Exhibits

10.1	Separation Agreement and Release between Harvard Bioscience, Inc. and Ken Olson, dated as of January 26, 2022 (previously filed as an exhibit to the Company’s Current Report on Form 8-K on January 28, 2022 and incorporated by reference thereto).
10.2	First Amendment to Credit Agreement and Amendment to Pledge and Security Agreement, dated April 27, 2022, among Harvard Bioscience, Inc., Citizens Bank, N.A., as the administrative agent, and the lenders party thereto (previously filed as an exhibit to the Company’s Current Report on Form 8-K on April 28, 2022 and incorporated by reference thereto).
31.1	Certification of Chief Financial Officer of Harvard Bioscience, Inc., pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Chief Executive Officer of Harvard Bioscience, Inc., pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*	Certification of Chief Financial Officer of Harvard Bioscience, Inc., pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*	Certification of Chief Financial Officer of Harvard Bioscience, Inc., pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS	Inline XBRL Instance Document
101.SCH	Inline XBRL Taxonomy Extension Schema Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Labels Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)
*	This certification shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by undersigned thereunto duly authorized.

	HARVARD BIOSCIENCE, INC.
Date: May 4, 2022
	By:	/s/ JAMES GREEN
		James Green
		Chief Executive Officer




	By:	/s/ MICHAEL A. ROSSI
		Michael A. Rossi
		Chief Financial Officer

EX-31.1 2 ex_362798.htm EXHIBIT 31.1 HTML Editor

EXHIBIT 31.1

Certification

I, Michael A. Rossi, certify that:

I have reviewed this Quarterly Report on Form 10-Q of Harvard Bioscience, Inc.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)), and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 4, 2022	/s/ MICHAEL A. ROSSI

	Michael A. Rossi
	Chief Financial Officer

EX-31.2 3 ex_362799.htm EXHIBIT 31.2 HTML Editor

EXHIBIT 31.2

Certification

I, James Green, certify that:

I have reviewed this Quarterly Report on Form 10-Q of Harvard Bioscience, Inc.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 4, 2022	/s/ JAMES GREEN

	James Green
	Chief Executive Officer

EX-32.1 4 ex_362800.htm EXHIBIT 32.1 HTML Editor

EXHIBIT 32.1

CERTIFICATION OF PERIODIC FINANCIAL REPORT PURSUANT TO 18 U.S.C. SECTION 1350

The undersigned officer of Harvard Bioscience, Inc. (the “Company”) hereby certifies to his knowledge that the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022 (the “Report”) to which this certification is being furnished as an exhibit, as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. This certification is provided solely pursuant to 18 U.S.C. Section 1350 and Item 601(b)(32) of Regulation S-K (Item 601(b)(32)) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), and the Exchange Act. In accordance with clause (ii) of Item 601(b)(32), this certification (A) shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and (B) shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

Date: May 4, 2022	/s/ MICHAEL A. ROSSI

	Name: Michael A. Rossi
	Title: Chief Financial Officer

EX-32.2 5 ex_362801.htm EXHIBIT 32.2 HTML Editor

EXHIBIT 32.2

CERTIFICATION OF PERIODIC FINANCIAL REPORT PURSUANT TO 18 U.S.C. SECTION 1350

Date: May 4, 2022	/s/ JAMES GREEN

	Name: James Green
	Title: Chief Executive Officer

EX-101.SCH 6 hbio-20220331.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Consolidated Balance Sheets (Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Consolidated Balance Sheets (Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Consolidated Statements of Operations (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Consolidated Statements of Comprehensive Income (Loss) (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) link:calculationLink link:definitionLink link:presentationLink 006 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 1 - Basis of Presentation and Summary of Significant Accounting Policies, and Risks and Uncertainties link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 2 - Recently Issued Accounting Pronouncements link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 3 - Goodwill and Intangible Assets link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 4 - Balance Sheet Information link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 5 - Restructuring and Other Exit Costs link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 7 - Leases link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 8 - Capital Stock and Stock-based Compensation link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 9 - Long-Term Debt link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 10 - Revenues link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 11 - Income Tax link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 12 - Commitments and Contingent Liabilities link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 13 - Subsequent Events link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 3 - Goodwill and Intangible Assets (Tables) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 4 - Balance Sheet Information (Tables) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 7 - Leases (Tables) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 8 - Capital Stock and Stock-based Compensation (Tables) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 9 - Long-Term Debt (Tables) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 10 - Revenues (Tables) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 3 - Goodwill and Intangible Assets (Details Textual) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 3 - Goodwill and Intangible Assets - Change in Carrying Amount of Goodwill (Details) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 3 - Goodwill and Intangible Assets - Intangible Assets (Details) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 3 - Goodwill and Intangible Assets - Future Amortization Expense of Intangible Assets (Details) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 4 - Balance Sheet Information - Inventories (Details) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 4 - Balance Sheet Information - Other Current Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 5 - Restructuring and Other Exit Costs (Details Textual) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 7 - Leases - Lease Expense (Details) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note 7 - Leases - Future Minimum Lease Payments (Details) link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note 8 - Capital Stock and Stock-based Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 040 - Disclosure - Note 8 - Capital Stock and Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details) link:calculationLink link:definitionLink link:presentationLink 041 - Disclosure - Note 8 - Capital Stock and Stock-based Compensation - Stock-based Compensation Expense (Details) link:calculationLink link:definitionLink link:presentationLink 042 - Disclosure - Note 8 - Capital Stock and Stock-based Compensation - Black Scholes Assumptions (Details) link:calculationLink link:definitionLink link:presentationLink 043 - Disclosure - Note 8 - Capital Stock and Stock-based Compensation - Weighted Average Number of Shares (Details) link:calculationLink link:definitionLink link:presentationLink 044 - Disclosure - Note 9 - Long-Term Debt (Details Textual) link:calculationLink link:definitionLink link:presentationLink 045 - Disclosure - Note 9 - Long-term Debt - Breakdown of Borrowings (Details) link:calculationLink link:definitionLink link:presentationLink 046 - Disclosure - Note 10 - Revenues (Details Textual) link:calculationLink link:definitionLink link:presentationLink 047 - Disclosure - Note 10 - Revenues - Disaggregation of Revenue (Details) link:calculationLink link:definitionLink link:presentationLink 049 - Disclosure - Note 10 - Revenues - Deferred Revenue (Details) link:calculationLink link:definitionLink link:presentationLink 050 - Disclosure - Note 10 - Revenues - Allowance for Doubtful Accounts (Details) link:calculationLink link:definitionLink link:presentationLink 051 - Disclosure - Note 11 - Income Tax (Details Textual) link:calculationLink link:definitionLink link:presentationLink 052 - Disclosure - Note 13 - Subsequent Events (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 7 hbio-20220331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 hbio-20220331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 hbio-20220331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Dividend yield us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo 2024 Case in Suffolk Superior Court [Member] Information regarding case of Suffolk Superior Court. Note To Financial Statement Details Textual us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree 2025 hbio_StockIssuedDuringPeriodValueIssuedForSettlement Stock Issued During Period, Value, Issued for Settlement Represent the value of stock issued for settlement. Significant Accounting Policies 2023 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths 2026 Note 3 - Goodwill and Intangible Assets 2024 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Note 4 - Balance Sheet Information Valuation Approach and Technique [Axis] Risk-free interest rate Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Note 7 - Leases Valuation Approach and Technique [Domain] Note 8 - Capital Stock and Stock-based Compensation Note 9 - Long-Term Debt us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths 2023 Note 10 - Revenues Note 3 - Goodwill and Intangible Assets - Change in Carrying Amount of Goodwill (Details) Amortization of intangible assets hbio_AmortizationOfIntangibleAssetsIncludingAmountsRelatedToDiscontinuedOperation The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets including portion attributable to discontinued operations, not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. Note 3 - Goodwill and Intangible Assets - Intangible Assets (Details) Income Tax Disclosure [Text Block] Note 3 - Goodwill and Intangible Assets - Future Amortization Expense of Intangible Assets (Details) Note 4 - Balance Sheet Information - Inventories (Details) Note 4 - Balance Sheet Information - Other Current Liabilities (Details) Lessee, Operating Lease, Liability, Maturity [Table Text Block] Volatility us-gaap_ShareBasedCompensation Stock-based compensation expense Note 7 - Leases - Lease Expense (Details) Other long-term assets Note 7- Leases - Supplemental Cash Flow Information Related to Operating Leases (Details) 2022 (remainder of year) us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear us-gaap_LiabilitiesCurrent Total current liabilities Note 7 - Leases - Supplemental Balance Sheet Information Related to Operating Leases (Details) Schedule of Debt [Table Text Block] Note 7 - Leases - Future Minimum Lease Payments (Details) Finite-Lived Intangible Assets, Weighted Average Useful Life (Year) Note 8 - Capital Stock and Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details) Other current liabilities Total Note 8 - Capital Stock and Stock-based Compensation - Stock-based Compensation Expense (Details) Note 8 - Capital Stock and Stock-based Compensation - Black Scholes Assumptions (Details) Note 8 - Capital Stock and Stock-based Compensation - Weighted Average Number of Shares (Details) Distribution Agreements/Customer Relationships [Member] Represents distribution agreements or customer relationships. Note 9 - Long-term Debt - Breakdown of Borrowings (Details) Note 10 - Revenues - Disaggregation of Revenue (Details) Note 10 - Segment and Related Information - Revenue by Geographic Destination (Details) Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Note 10 - Revenues - Deferred Revenue (Details) Estimated Litigation Liability, Current Note 10 - Revenues - Allowance for Doubtful Accounts (Details) Thereafter hbio_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Notes To Financial Statements Service, Maintenance, and Warranty Contracts [Member] Represents service, maintenance, and warranty contracts. Notes To Financial Statements [Abstract] Instruments, Equipment, Software, and Accessories [Member] Represents instruments, equipment, software, and accessories. Rest of the World [Member] Represents the rest of the world. Restricted Stock Units Granted , Grant Date Fair Value, Balance (in dollars per share) Customer Advances [Member] Represents customer advances. Restricted Stock Units, Vested , Grant Date Fair Value, Balance (in dollars per share) Restricted Stock Units, Cancelled/ Forfeited , Grant Date Fair Value, Balance (in dollars per share) Settlement of litigation - Note 13 us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Restricted Stock Units Outstanding , Grant Date Fair Value, Balance (in dollars per share) Restricted Stock Units Outstanding , Grant Date Fair Value, Balance (in dollars per share) Foreign currency translation adjustments us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Restricted Stock Units, Cancelled / Forfeited in Period (in shares) hbio_FinitelivedIntangibleAssetExpectedAmortizationAfterYearFour Thereafter Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Restricted Stock Units Outstanding , Balance (in shares) Restricted Stock Units Outstanding , Balance (in shares) Depreciation Restricted Stock Units, Granted in Period (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Restricted Stock Units, Vested in Period (in shares) us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation Shares withheld for taxes (in shares) us-gaap_LongTermDebtCurrent Current portion of long-term debt Other comprehensive income (loss) us-gaap_AssetsCurrent Total current assets Schedule Of Stock Options And Restricted Stock Units Activity Roll forward [Table Text Block] Tabular representation of the roll forward of stock options and restricted stock units at the end of the reporting period Market Condition Restricted Stock Units [Member] Represents information related to market condition restricted stock units. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) Interest expense Common stock, par value $0.01 per share, 80,000,000 shares authorized: 41,241,449 shares issued and outstanding at March 31, 2022; 41,142,876 shares issued and outstanding at December 31, 2021 Adjustments to reconcile net loss to net cash provided by operating activities: Current portion of long-term debt us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Options, Outstanding, Weighted Average Exercise Price (in dollars per share) Options, Outstanding, Weighted Average Exercise Price (in dollars per share) Common stock, shares authorized (in shares) Common stock, shares issued (in shares) Deferred revenue Options, Cancelled / Forfeited, Weighted Average Exercise Price (in dollars per share) Common stock, par value (in dollars per share) Correlation coefficient The correlation coefficient assumption that is used in valuing an option on its own shares. Goodwill and Intangible Assets Disclosure [Text Block] Schedule of Goodwill [Table Text Block] Options, Granted in Period, Weighted Average Exercise Price (in dollars per share) Black Scholes Option Pricing Model [Member] Represents Black Scholes Option-pricing model. Options, exercised, weighted average exercise price (in dollars per share) Compensation us-gaap_EmployeeRelatedLiabilitiesCurrent Term Loan [Member] Represents information related to term loan. Accrued income taxes us-gaap_AccruedIncomeTaxesCurrent Statistical Measurement [Domain] hbio_DebtInstrumentQuarterlyPaymentCurrentYear Debt Instrument, Quarterly Payment, Current Year Amount of the required quarterly payments including both interest and principal payments for the current fiscal year. Cash paid for amounts included in the measurement of lease liabilities: Maximum [Member] Lessee, Operating Leases [Text Block] Minimum [Member] Accounts payable Revolving Credit Facility [Member] Product and Service [Axis] Other current assets us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Opening Balance, Stock Options Outstanding (in shares) Opening Balance, Stock Options Outstanding (in shares) hbio_DebtInstrumentQuarterlyPaymentThereafter Debt Instrument, Quarterly Payment, Thereafter Amount of the required quarterly payments including both interest and principal payments thereafter Product and Service [Domain] Statistical Measurement [Axis] Litigation Case [Axis] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Options, Cancelled / Forfeited in Period (in shares) Credit Facility [Axis] Litigation Case [Domain] Credit Facility [Domain] Preferred stock, par value $0.01 per share, 5,000,000 shares authorized Other us-gaap_OtherAccruedLiabilitiesCurrent Cash paid for interest us-gaap_PolicyTextBlockAbstract Accounting Policies Preferred stock, par value (in dollars per share) Geographical [Axis] Geographical [Domain] Trade Names and Patents [Member] Information pertaining to trade names and patents. Preferred stock, shares authorized (in shares) Warranty costs us-gaap_ProductWarrantyAccrualClassifiedCurrent Europe [Member] Inventories Total Professional fees us-gaap_AccruedProfessionalFeesCurrent us-gaap_PaymentsToAcquireIntangibleAssets Additions to intangible assets hbio_DeferredIncomeTaxExpenseBenefitIncludingDiscontinuedOperation Deferred income taxes and other Represents deferred income tax expense (benefit) including discontinued operations. us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Additions to property, plant and equipment Weighted-average common shares: Cash paid (received) for income taxes, net of refunds Current liabilities: Supplemental Balance Sheet Disclosures [Text Block] Supplemental disclosures of cash flow information: us-gaap_Assets Total assets Shareholders' Equity and Share-Based Payments [Text Block] us-gaap_OperatingLeaseExpense Operating Lease, Expense us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total Cash flows from operating activities: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) us-gaap_SubleaseIncome Sublease income Statement [Line Items] Accounts receivable, net Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Additional paid-in-capital AOCI Attributable to Parent [Member] us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation Shares withheld for taxes Stockholders' equity: us-gaap_LossContingencyEstimateOfPossibleLoss Loss Contingency, Estimate of Possible Loss Other income (expense), net us-gaap_NonoperatingIncomeExpense Total other expense Award Type [Domain] Current assets: Award Type [Axis] Net loss Net loss Net loss The Credit Agreement [Member] Information pertaining to the credit agreement. us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Total amortizable intangible assets Finite-Lived Intangible Assets, Net Total us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Total intangible assets, Net Intangible assets, net The Lenders [Member] Information pertaining to the lenders. Effect of exchange rate changes on cash us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Decrease in cash and cash equivalents Restricted Stock Units (RSUs) [Member] Finite-Lived Intangible Assets, Gross us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash provided by (used in) financing activities us-gaap_Liabilities Total liabilities Commitments and contingencies - Note 12 Swingline Loan Facility [Member] Information pertaining to the swingline loan sub-facility. hbio_DebtInstrumentCurrentMaturitiesExcessCashFlowSweep Debt Instrument, Current Maturities, Excess Cash Flow Sweep Information on the excess cash flow sweep. us-gaap_OperatingIncomeLoss Operating loss us-gaap_ContractWithCustomerLiabilityRevenueRecognized Contract with Customer, Liability, Revenue Recognized Share-Based Payment Arrangement, Option [Member] us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash (used in) provided by operating activities Other (expense) income: us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used in investing activities The ABR Loan [Member] Information pertaining to the ABR loan. Effect of change in currency translation The LIBOR Loan and Pricing Grid Credit Agreement [Member] Information pertaining to the LIBOR loan and pricing grid credit agreement. us-gaap_GrossProfit Gross profit Base Rate [Member] Cost of revenues hbio_DebtInstrumentInterestRateStateFloorPercentage Debt Instrument, Interest Rate, State Floor Percentage Represents the stated floor percentage rate. Indefinite-lived intangible assets: EX-101.PRE 10 hbio-20220331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2022	Apr. 29, 2022
Document Information [Line Items]
Entity Central Index Key	0001123494
Entity Registrant Name	HARVARD BIOSCIENCE INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	001-33957
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-3306140
Entity Address, Address Line One	84 October Hill Road
Entity Address, City or Town	Holliston
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01746
City Area Code	508
Local Phone Number	893-8999
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	HBIO
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		41,241,449

XML 12 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 5,433	$ 7,821
Accounts receivable, net	20,274	21,834
Inventories	28,711	27,587
Other current assets	5,030	4,341
Total current assets	59,448	61,583
Property, plant and equipment, net	3,499	3,415
Operating lease right-of-use assets	6,605	6,897
Goodwill	57,356	57,689
Intangible assets, net	25,878	27,385
Other long-term assets	5,258	5,375
Total assets	158,044	162,344
Current liabilities:
Current portion of long-term debt	2,720	3,235
Current portion, operating lease liabilities	2,151	2,142
Accounts payable	6,218	4,911
Deferred revenue	3,956	4,266
Other current liabilities	12,181	10,762
Total current liabilities	27,226	25,316
Long-term debt, net	46,244	45,095
Deferred tax liability	1,442	1,558
Operating lease liabilities	6,159	6,488
Other long-term liabilities	598	486
Total liabilities	81,669	78,943
Commitments and contingencies - Note 12
Stockholders' equity:
Preferred stock, par value $0.01 per share, 5,000,000 shares authorized	0	0
Common stock, par value $0.01 per share, 80,000,000 shares authorized: 41,241,449 shares issued and outstanding at March 31, 2022; 41,142,876 shares issued and outstanding at December 31, 2021	452	452
Additional paid-in-capital	226,203	225,650
Accumulated deficit	(139,554)	(132,674)
Accumulated other comprehensive loss	(10,726)	(10,027)
Total stockholders' equity	76,375	83,401
Total liabilities and stockholders' equity	$ 158,044	$ 162,344

XML 13 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	80,000,000	80,000,000
Common stock, shares issued (in shares)	41,241,449	41,142,876
Common stock, shares outstanding (in shares)	41,241,449	41,142,876

XML 14 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenues	$ 28,778	$ 26,989
Cost of revenues	12,601	11,558
Gross profit	16,177	15,431
Sales and marketing expenses	6,687	5,386
General and administrative expenses	6,325	6,333
Research and development expenses	3,220	2,487
Amortization of intangible assets	1,466	1,464
Settlement of litigation - Note 13	5,191	0
Total operating expenses	22,889	15,670
Operating loss	(6,712)	(239)
Other (expense) income:
Interest expense	(384)	(411)
Other income (expense), net	78	(34)
Total other expense	(306)	(445)
Loss before income taxes	(7,018)	(684)
Income tax benefit	(138)	(15)
Net loss	$ (6,880)	$ (669)
Loss per share:
Basic and diluted loss per common share (in dollars per share)	$ (0.17)	$ (0.02)
Weighted-average common shares:
Basic and diluted (in shares)	41,219	39,787

XML 15 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Net loss	$ (6,880)	$ (669)
Other comprehensive loss:
Foreign currency translation adjustments	(699)	(1,325)
Comprehensive loss	$ (7,579)	$ (1,994)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

XML 16 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Treasury Stock [Member]	Total
Balance (in shares) at Dec. 31, 2020	47,153,000
Balance at Dec. 31, 2020	$ 444	$ 232,357	$ (132,386)	$ (13,066)	$ (10,668)	$ 76,681
Stock option exercises (in shares)	311,000
Stock option exercises	$ 4	1,920	0	0	0	1,924
Vesting of restricted stock units (in shares)	340,000
Vesting of restricted stock units	$ 0	0	0	0	0	0
Shares withheld for taxes (in shares)	(108,000)
Shares withheld for taxes	$ 0	(464)	0	0	0	(464)
Stock-based compensation expense	0	968	0	0	0	968
Net loss	0	0	(669)	0	0	(669)
Other comprehensive income (loss)	$ 0	0	0	(1,325)	0	(1,325)
Balance (in shares) at Mar. 31, 2021	47,696,000
Balance at Mar. 31, 2021	$ 448	234,781	(133,055)	(14,391)	(10,668)	77,115
Balance (in shares) at Dec. 31, 2021	41,143,000
Balance at Dec. 31, 2021	$ 452	225,650	(132,674)	(10,027)	0	$ 83,401
Stock option exercises (in shares)	11,000					10,987
Stock option exercises	$ 0	31	0	0	0	$ 31
Vesting of restricted stock units (in shares)	151,000
Vesting of restricted stock units	$ 0	0	0	0	0	0
Shares withheld for taxes (in shares)	(64,000)
Shares withheld for taxes	$ 0	(501)	0	0	0	(501)
Stock-based compensation expense	0	1,023	0	0	0	1,023
Net loss	0	0	(6,880)	0	0	(6,880)
Other comprehensive income (loss)	$ 0	0	0	(699)	0	(699)
Balance (in shares) at Mar. 31, 2022	41,241,000
Balance at Mar. 31, 2022	$ 452	$ 226,203	$ (139,554)	$ (10,726)	$ 0	$ 76,375

XML 17 R7.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net loss	$ (6,880)	$ (669)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation	382	445
Amortization of intangible assets	1,466	1,464
Amortization of deferred financing costs	70	70
Stock-based compensation expense	1,023	968
Deferred income taxes and other	(123)	(53)
Changes in operating assets and liabilities:
Accounts receivable	1,506	584
Inventories	(1,308)	(602)
Other assets	(466)	(94)
Accounts payable and accrued expenses	2,729	(245)
Deferred revenue	(300)	(135)
Other liabilities	(85)	(696)
Net cash (used in) provided by operating activities	(1,986)	1,037
Cash flows from investing activities:
Additions to property, plant and equipment	(471)	(151)
Additions to intangible assets	0	(150)
Net cash used in investing activities	(471)	(301)
Cash flows from financing activities:
Borrowing from revolving line of credit	1,500	0
Repayment of revolving line of credit	0	(4,000)
Repayment of term debt	(936)	(500)
Debt issuance costs	0	(101)
Proceeds from exercise of stock options	31	1,924
Taxes paid related to net share settlement of equity awards	(501)	(464)
Net cash provided by (used in) financing activities	94	(3,141)
Effect of exchange rate changes on cash	(25)	(97)
Decrease in cash and cash equivalents	(2,388)	(2,502)
Cash and cash equivalents at beginning of period	7,821	8,317
Cash and cash equivalents at end of period	5,433	5,815
Supplemental disclosures of cash flow information:
Cash paid for interest	383	458
Cash paid (received) for income taxes, net of refunds	$ 107	$ (113)

XML 18 R8.htm IDEA: XBRL DOCUMENT

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies, and Risks and Uncertainties

3 Months Ended

Mar. 31, 2022

Notes to Financial Statements

Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]

1.	Basis of Presentation and Summary of Significant Accounting Policies, and Risks and Uncertainties

Basis of Presentation and Summary of Significant Accounting Policies

Risks and Uncertainties

XML 19 R9.htm IDEA: XBRL DOCUMENT

Note 2 - Recently Issued Accounting Pronouncements

3 Months Ended

Mar. 31, 2022

Notes to Financial Statements

Accounting Standards Update and Change in Accounting Principle [Text Block]

2.	Recently Issued Accounting Pronouncements

Accounting Pronouncements to be Adopted

- Definition

The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-URI https://asc.fasb.org/topic&trid=2122394

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (d)(1)
-URI https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (d)(2)
-URI https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 11.M.Q2)
-URI https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(2)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(2)
-URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (f)(1)
-URI https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(2)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (c)(2)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (f)(3)
-URI https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (c)(1)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (c)(3)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(3)
-URI https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(3)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 2
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(3)
-URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277

+ Details

XML 20 R10.htm IDEA: XBRL DOCUMENT

Note 3 - Goodwill and Intangible Assets

3 Months Ended

Mar. 31, 2022

Notes to Financial Statements

Goodwill and Intangible Assets Disclosure [Text Block]

3.	Goodwill and Intangible Assets

Goodwill

The change in the carrying amount of goodwill for the three months ended March 31, 2022, were as follows:

(in thousands)
Carrying amount at December 31, 2021	$	57,689
Effect of change in currency translation		(333	)
Carrying amount at March 31, 2022	$	57,356

Intangible Assets

Identifiable intangible assets at March 31, 2022 and December 31, 2021 consist of the following:

			March 31, 2022							December 31, 2021
(in thousands)	Average				Accumulated							Accumulated
Amortizable intangible assets:	Life*		Gross		Amortization			Net		Gross		Amortization			Net
Distribution agreements/customer relationships		7.7	$	17,594	$	(8,938	)	$	8,656	$	17,689	$	(8,675	)	$	9,014
Existing technology		3.9		38,611		(24,786	)		13,825		38,707		(23,962	)		14,745
Trade names and patents		4.2		8,467		(5,304	)		3,163		8,496		(5,108	)		3,388
Total amortizable intangible assets			$	64,672	$	(39,028	)	$	25,644	$	64,892	$	(37,745	)	$	27,147
Indefinite-lived intangible assets:									234							238
Total intangible assets								$	25,878						$	27,385

* Weighted average life in years as of March 31, 2022

	Amortization
Year Ending December 31,	Expense
(in thousands)
2022 (remainder of year)	$	4,366
2023		5,728
2024		5,427
2025		4,109
2026		2,368
Thereafter		3,646
Total	$	25,644

XML 21 R11.htm IDEA: XBRL DOCUMENT

Note 4 - Balance Sheet Information

3 Months Ended

Mar. 31, 2022

Notes to Financial Statements

Supplemental Balance Sheet Disclosures [Text Block]

4.	Balance Sheet Information

The following tables provide details of selected balance sheet items as of the periods indicated:

*Inventories:*	March 31,		December 31,
(in thousands)	2022		2021
Finished goods	$	6,798	$	5,646
Work in process		3,439		3,410
Raw materials		18,474		18,531
Total	$	28,711	$	27,587

*Other Current Liabilities:*	March 31,		December 31,
(in thousands)	2022		2021
Compensation	$	2,878	$	6,048
Professional fees		396		480
Warranty costs		242		240
Customer related costs		2,058		2,265
Settlement of litigation		4,814		-
Accrued income taxes		141		224
Other		1,653		1,505
Total	$	12,181	$	10,762

XML 22 R12.htm IDEA: XBRL DOCUMENT

Note 5 - Restructuring and Other Exit Costs

3 Months Ended

Mar. 31, 2022

Notes to Financial Statements

Restructuring and Related Activities Disclosure [Text Block]

5.	Restructuring and Other Exit Costs

XML 23 R13.htm IDEA: XBRL DOCUMENT

Note 6 - Related Party Transactions

3 Months Ended

Mar. 31, 2022

Notes to Financial Statements

6.	Related Party Transactions

XML 24 R14.htm IDEA: XBRL DOCUMENT

Note 7 - Leases

3 Months Ended

Mar. 31, 2022

Notes to Financial Statements

Lessee, Operating Leases [Text Block]

7.	Leases

The Company has noncancelable operating leases for offices, manufacturing facilities, warehouse space, automobiles and equipment expiring at various dates through 2030.

The components of lease expense for the three months ended March 31, 2022 and 2021, are as follows:

	Three Months Ended March 31,
(in thousands)	2022			2021
Operating lease cost	$	504		$	517
Short-term lease cost		64			46
Sublease income		(25	)		(25	)
Total lease cost	$	543		$	538

Supplemental cash flow information related to the Company's operating leases was as follows:

	Three Months Ended March 31,
(in thousands)	2022		2021
Cash paid for amounts included in the measurement of lease liabilities:	$	594	$	611
Right-of-use assets obtained in exchange for lease obligations:	$	39	$	-

Supplemental balance sheet information related to the Company's operating leases was as follows:

	March 31,			December 31,
(in thousands)	2022			2021
Operating lease right-of-use assets	$	6,605		$	6,897

Current portion, operating lease liabilities	$	2,151		$	2,142
Operating lease liabilities, long-term		6,159			6,488
Total operating lease liabilities	$	8,310		$	8,630

Weighted average remaining lease term (years)		6.5			6.7
Weighted average discount rate		9.3	%		9.3	%

Future minimum lease payments for operating leases for each twelve-month period subsequent to March 31, 2022, are as follows:

Year Ending December 31,
(in thousands)
2022 (remainder of year)	$	1,611
2023		2,133
2024		1,765
2025		1,019
2026		980
Thereafter		3,871
Total lease payments		11,379
Less imputed interest		(3,069	)
Total operating lease liabilities	$	8,310

XML 25 R15.htm IDEA: XBRL DOCUMENT

Note 8 - Capital Stock and Stock-based Compensation

3 Months Ended

Mar. 31, 2022

Notes to Financial Statements

Shareholders' Equity and Share-Based Payments [Text Block]

8.	Capital Stock and Stock-Based Compensation

Stock-Based Payment Awards

				Weighted
	*Stock*			*Average*		*Time-Based*					*Performance-*
	*Options*			*Exercise*		*RSUs*			*Grant Date*		*Based RSUs*		*Grant Date*
	*Outstanding*			*Price*		*Outstanding*			*Fair Value*		*Outstanding*		*Fair Value*
Balance at December 31, 2021		1,404,816		$	3.10		1,141,164		$	3.57		860,155	$	3.13
Granted		-			-		518,163			5.52		205,122		5.92
Exercised		(10,987	)		2.78		-			-		-		-
Vested (RSUs)		-			-		(151,185	)		2.30		-		-
Cancelled/Forfeited		(3,126	)		3.79		(12,917	)		3.07		-		-
Balance at March 31, 2022		1,390,703		$	3.10		1,495,225		$	4.37		1,065,277	$	3.67

Stock-based compensation expense for the three months ended March 31, 2022 and 2021, was allocated as follows:

	Three Months Ended March 31,
(in thousands)	2022		2021
Cost of revenues	$	36	$	20
Sales and marketing expenses		154		93
General and administrative expenses		791		834
Research and development expenses		42		21
Total stock-based compensation expenses	$	1,023	$	968

	2022
Volatility		65.1	%
Risk-free interest rate		1.4	%
Correlation coefficient		38.5	%
Dividend yield		-	%

Earnings (Loss) Per Share

	Three Months Ended March 31,
(in thousands)	2022		2021
Basic		41,219		39,787
Dilutive effect of equity awards		-		-
Diluted		41,219		39,787

XML 26 R16.htm IDEA: XBRL DOCUMENT

Note 9 - Long-Term Debt

3 Months Ended

Mar. 31, 2022

Notes to Financial Statements

Long-Term Debt [Text Block]

9.	Long-Term Debt

As of March 31, 2022 and December 31, 2021, the Company’s borrowings were comprised of:

	March 31,			December 31,
(in thousands)	2022			2021
Long-term debt:
Term loan	$	37,064		$	38,000
Revolving line		12,950			11,450
Less unamortized deferred financing costs		(1,050	)		(1,120	)
Total debt		48,964			48,330
Current portion of long-term debt		(3,000	)		(3,515	)
Current unamortized deferred financing costs		280			280
Long-term debt	$	46,244		$	45,095

XML 27 R17.htm IDEA: XBRL DOCUMENT

Note 10 - Revenues

3 Months Ended

Mar. 31, 2022

Notes to Financial Statements

Revenue from Contract with Customer [Text Block]

10.

Revenues

The following tables represent a disaggregation of revenue from contracts with customers for the three months ended March 31, 2022 and 2021:

	Three Months Ended March 31,
(in thousands)	2022		2021
Instruments, equipment, software and accessories	$	27,538	$	25,827
Service, maintenance and warranty contracts		1,240		1,162
Total revenues	$	28,778	$	26,989

The following tables represent a disaggregation of revenue by geographic destination for the three months ended March 31, 2022 and 2021:

	Three Months Ended March 31,
(in thousands)	2022		2021
United States	$	12,239	$	11,177
Europe		7,823		8,589
Asia		6,733		5,538
Rest of the world		1,983		1,685
Total revenues	$	28,778	$	26,989

Deferred revenue

The following tables provide details of deferred revenue as of the periods indicated:

	March 31,		December 31,
(in thousands)	2022		2021
Service contracts	$	1,995	$	1,976
Customer advances		1,961		2,290
Total deferred revenue	$	3,956	$	4,266

Allowance for Doubtful Accounts

Allowance for doubtful accounts is based on the Company’s assessment of the collectability of accounts receivable. Activity in the allowance for doubtful accounts is as follows:

	Three Months Ended March 31,
(in thousands)	2022			2021
Balance, beginning of period	$	136		$	227
Bad debt (credit) expense		(6	)		5
Charge-offs and other		6			22
Balance, end of period	$	136		$	254

Concentrations

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI https://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

+ Details

XML 28 R18.htm IDEA: XBRL DOCUMENT

Note 11 - Income Tax

3 Months Ended

Mar. 31, 2022

Notes to Financial Statements

Income Tax Disclosure [Text Block]

11.

Income Tax

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

XML 29 R19.htm IDEA: XBRL DOCUMENT

Note 12 - Commitments and Contingent Liabilities

3 Months Ended

Mar. 31, 2022

Notes to Financial Statements

Commitments and Contingencies Disclosure [Text Block]

12.

Commitments and Contingent Liabilities

XML 30 R20.htm IDEA: XBRL DOCUMENT

Note 13 - Subsequent Events

3 Months Ended

Mar. 31, 2022

Notes to Financial Statements

Subsequent Events [Text Block]

13.

Subsequent Events

Litigation Settlement

Credit Agreement Amendment

On April 28, 2022, the Company entered into an amendment to the Credit Agreement and Pledge and Security Agreement (the “Amendment”), among the Company, the Lenders, and Citizens Bank, N.A., as the administrative agent (the “Administrative Agent”). Pursuant to the Amendment, the Lenders and the Administrative Agent have agreed, among other things, (i) to modify the financial covenant relating to the consolidated net leverage ratio and (ii) to consent to the Settlement described above. In consideration for the Amendment, the Company paid a fee of $0.2 million to the Lenders and the Administrative Agent.

XML 31 R21.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)	3 Months Ended
Significant Accounting Policies (Policies)	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	*Basis of Presentation and Summary of Significant Accounting Policies* The unaudited consolidated financial statements of Harvard Bioscience, Inc. and its wholly-owned subsidiaries (collectively, “Harvard Bioscience” or the “Company”) as of March 31, 2022 and for the three months ended March 31, 2022 and 2021, have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. The December 31, 2021, consolidated balance sheet was derived from audited financial statements but does not include all disclosures required by U.S. GAAP. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021. In the opinion of management, all adjustments, which include normal recurring adjustments necessary to present a fair statement of financial position as of March 31, 2022, results of operations and comprehensive loss and cash flows for the three months ended March 31, 2022 and 2021, as applicable, have been made. The results of operations for the three months ended March 31, 2022, are not necessarily indicative of the operating results for the full fiscal year or any future periods. The accounting policies underlying the accompanying unaudited consolidated financial statements are set forth in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. There have been no material changes in the Company’s significant accounting policies during the three months ended March 31, 2022.
Risks and Uncertainties Policy [Policy Text Block]	*Risks and Uncertainties* On March 11, 2020, the World Health Organization declared the outbreak of a novel coronavirus (COVID-19) as a pandemic. The COVID-19 pandemic has had a negative impact on the Company’s operations to date and the future impacts of the pandemic and any resulting economic impact are largely unknown and rapidly evolving. Since the global outbreak of COVID-19, many customers, particularly academic research institutions, have reduced laboratory work which has negatively impacted, and will continue to negatively impact, the Company’s sales. Also, countries world-wide continue to issue COVID-19 related policies in an attempt to control the pandemic. In particular, during the beginning of 2022, China implemented area-wide shutdowns in order to control the spread of COVID-19. To ensure business continuity while maintaining a safe environment for employees aligned with guidance from government and health organizations, the Company transitioned a significant portion of its workforce to work-from-home while implementing social distancing requirements and other measures to allow manufacturing and other personnel essential to production to continue work within the Company's facilities. Business travel was significantly reduced during this period. While a portion of the workforce has returned to in-office work and travel is less restricted, the Company continued to have restrictions which represent disruptions that can impact productivity including sales and marketing activities. The global supply chain has experienced significant disruptions due to electronic component and labor shortages and other macroeconomic factors which have emerged since the onset of COVID-19, leading to increased cost of freight, purchased materials, and manufacturing labor costs, while also delaying customer shipments. Accordingly, these conditions in addition to the overall impact on the global economy have negatively impacted results of operations and cash flows.

XML 32 R22.htm IDEA: XBRL DOCUMENT

Note 3 - Goodwill and Intangible Assets (Tables)

3 Months Ended

Mar. 31, 2022

Notes Tables

Schedule of Goodwill [Table Text Block]

(in thousands)
Carrying amount at December 31, 2021	$	57,689
Effect of change in currency translation		(333	)
Carrying amount at March 31, 2022	$	57,356

Schedule of Intangible Assets and Goodwill [Table Text Block]

			March 31, 2022							December 31, 2021
(in thousands)	Average				Accumulated							Accumulated
Amortizable intangible assets:	Life*		Gross		Amortization			Net		Gross		Amortization			Net
Distribution agreements/customer relationships		7.7	$	17,594	$	(8,938	)	$	8,656	$	17,689	$	(8,675	)	$	9,014
Existing technology		3.9		38,611		(24,786	)		13,825		38,707		(23,962	)		14,745
Trade names and patents		4.2		8,467		(5,304	)		3,163		8,496		(5,108	)		3,388
Total amortizable intangible assets			$	64,672	$	(39,028	)	$	25,644	$	64,892	$	(37,745	)	$	27,147
Indefinite-lived intangible assets:									234							238
Total intangible assets								$	25,878						$	27,385

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

	Amortization
Year Ending December 31,	Expense
(in thousands)
2022 (remainder of year)	$	4,366
2023		5,728
2024		5,427
2025		4,109
2026		2,368
Thereafter		3,646
Total	$	25,644

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1A
-URI https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 55
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

+ Details

XML 33 R23.htm IDEA: XBRL DOCUMENT

Note 4 - Balance Sheet Information (Tables)

3 Months Ended

Mar. 31, 2022

Notes Tables

Schedule of Inventory, Current [Table Text Block]

*Inventories:*	March 31,		December 31,
(in thousands)	2022		2021
Finished goods	$	6,798	$	5,646
Work in process		3,439		3,410
Raw materials		18,474		18,531
Total	$	28,711	$	27,587

Other Current Liabilities [Table Text Block]

*Other Current Liabilities:*	March 31,		December 31,
(in thousands)	2022		2021
Compensation	$	2,878	$	6,048
Professional fees		396		480
Warranty costs		242		240
Customer related costs		2,058		2,265
Settlement of litigation		4,814		-
Accrued income taxes		141		224
Other		1,653		1,505
Total	$	12,181	$	10,762

XML 34 R24.htm IDEA: XBRL DOCUMENT

Note 7 - Leases (Tables)

3 Months Ended

Mar. 31, 2022

Notes Tables

Lease, Cost [Table Text Block]

	Three Months Ended March 31,
(in thousands)	2022			2021
Operating lease cost	$	504		$	517
Short-term lease cost		64			46
Sublease income		(25	)		(25	)
Total lease cost	$	543		$	538

Supplemental Cash Flow Information Related to Operating Leases [Table Text Block]

	Three Months Ended March 31,
(in thousands)	2022		2021
Cash paid for amounts included in the measurement of lease liabilities:	$	594	$	611
Right-of-use assets obtained in exchange for lease obligations:	$	39	$	-

Supplemental Balance Sheet Informaton Related to Operating Leases [Table Text Block]

	March 31,			December 31,
(in thousands)	2022			2021
Operating lease right-of-use assets	$	6,605		$	6,897

Current portion, operating lease liabilities	$	2,151		$	2,142
Operating lease liabilities, long-term		6,159			6,488
Total operating lease liabilities	$	8,310		$	8,630

Weighted average remaining lease term (years)		6.5			6.7
Weighted average discount rate		9.3	%		9.3	%

Lessee, Operating Lease, Liability, Maturity [Table Text Block]

Year Ending December 31,
(in thousands)
2022 (remainder of year)	$	1,611
2023		2,133
2024		1,765
2025		1,019
2026		980
Thereafter		3,871
Total lease payments		11,379
Less imputed interest		(3,069	)
Total operating lease liabilities	$	8,310

XML 35 R25.htm IDEA: XBRL DOCUMENT

Note 8 - Capital Stock and Stock-based Compensation (Tables)

3 Months Ended

Mar. 31, 2022

Notes Tables

Schedule Of Stock Options And Restricted Stock Units Activity Roll forward [Table Text Block]

				Weighted
	*Stock*			*Average*		*Time-Based*					*Performance-*
	*Options*			*Exercise*		*RSUs*			*Grant Date*		*Based RSUs*		*Grant Date*
	*Outstanding*			*Price*		*Outstanding*			*Fair Value*		*Outstanding*		*Fair Value*
Balance at December 31, 2021		1,404,816		$	3.10		1,141,164		$	3.57		860,155	$	3.13
Granted		-			-		518,163			5.52		205,122		5.92
Exercised		(10,987	)		2.78		-			-		-		-
Vested (RSUs)		-			-		(151,185	)		2.30		-		-
Cancelled/Forfeited		(3,126	)		3.79		(12,917	)		3.07		-		-
Balance at March 31, 2022		1,390,703		$	3.10		1,495,225		$	4.37		1,065,277	$	3.67

Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

	Three Months Ended March 31,
(in thousands)	2022		2021
Cost of revenues	$	36	$	20
Sales and marketing expenses		154		93
General and administrative expenses		791		834
Research and development expenses		42		21
Total stock-based compensation expenses	$	1,023	$	968

Schedule of Weighted Average Number of Shares [Table Text Block]

	Three Months Ended March 31,
(in thousands)	2022		2021
Basic		41,219		39,787
Dilutive effect of equity awards		-		-
Diluted		41,219		39,787

Black Scholes Option Pricing Model [Member]

Notes Tables

Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	2022
Volatility		65.1	%
Risk-free interest rate		1.4	%
Correlation coefficient		38.5	%
Dividend yield		-	%

XML 36 R26.htm IDEA: XBRL DOCUMENT

Note 9 - Long-Term Debt (Tables)

3 Months Ended

Mar. 31, 2022

Notes Tables

Schedule of Debt [Table Text Block]

	March 31,			December 31,
(in thousands)	2022			2021
Long-term debt:
Term loan	$	37,064		$	38,000
Revolving line		12,950			11,450
Less unamortized deferred financing costs		(1,050	)		(1,120	)
Total debt		48,964			48,330
Current portion of long-term debt		(3,000	)		(3,515	)
Current unamortized deferred financing costs		280			280
Long-term debt	$	46,244		$	45,095

XML 37 R27.htm IDEA: XBRL DOCUMENT

Note 10 - Revenues (Tables)

3 Months Ended

Mar. 31, 2022

Notes Tables

Disaggregation of Revenue [Table Text Block]

	Three Months Ended March 31,
(in thousands)	2022		2021
Instruments, equipment, software and accessories	$	27,538	$	25,827
Service, maintenance and warranty contracts		1,240		1,162
Total revenues	$	28,778	$	26,989

Revenue from External Customers by Geographic Areas [Table Text Block]

	Three Months Ended March 31,
(in thousands)	2022		2021
United States	$	12,239	$	11,177
Europe		7,823		8,589
Asia		6,733		5,538
Rest of the world		1,983		1,685
Total revenues	$	28,778	$	26,989

Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]

	March 31,		December 31,
(in thousands)	2022		2021
Service contracts	$	1,995	$	1,976
Customer advances		1,961		2,290
Total deferred revenue	$	3,956	$	4,266

Financing Receivable, Allowance for Credit Loss [Table Text Block]

	Three Months Ended March 31,
(in thousands)	2022			2021
Balance, beginning of period	$	136		$	227
Bad debt (credit) expense		(6	)		5
Charge-offs and other		6			22
Balance, end of period	$	136		$	254

XML 38 R28.htm IDEA: XBRL DOCUMENT

Note 3 - Goodwill and Intangible Assets (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Amortization of Intangible Assets	$ 1,466	$ 1,464

XML 39 R29.htm IDEA: XBRL DOCUMENT

Note 3 - Goodwill and Intangible Assets - Change in Carrying Amount of Goodwill (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2022 USD ($)
Carrying amount at December 31, 2021	$ 57,689
Effect of change in currency translation	(333)
Carrying amount at March 31, 2022	$ 57,356

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References + Details

XML 40 R30.htm IDEA: XBRL DOCUMENT

Note 3 - Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2022

Dec. 31, 2021

Finite-Lived Intangible Assets, Gross

$ 64,672

$ 64,892

Total amortizable intangible assets

(39,028)

(37,745)

Finite-Lived Intangible Assets, Net

25,644

27,147

Indefinite-lived intangible assets:

234

238

Total intangible assets, Net

$ 25,878

27,385

Distribution Agreements/Customer Relationships [Member]

Finite-Lived Intangible Assets, Weighted Average Useful Life (Year)

^[1]

7 years 8 months 12 days

Finite-Lived Intangible Assets, Gross

$ 17,594

17,689

Total amortizable intangible assets

(8,938)

(8,675)

Finite-Lived Intangible Assets, Net

$ 8,656

9,014

Existing Technology [Member]

Finite-Lived Intangible Assets, Weighted Average Useful Life (Year)

^[1]

3 years 10 months 24 days

Finite-Lived Intangible Assets, Gross

$ 38,611

38,707

Total amortizable intangible assets

(24,786)

(23,962)

Finite-Lived Intangible Assets, Net

$ 13,825

14,745

Trade Names and Patents [Member]

Finite-Lived Intangible Assets, Weighted Average Useful Life (Year)

^[1]

4 years 2 months 12 days

Finite-Lived Intangible Assets, Gross

$ 8,467

8,496

Total amortizable intangible assets

(5,304)

(5,108)

Finite-Lived Intangible Assets, Net

$ 3,163

$ 3,388

[1]	Weighted average life in years as of December 31, 2021

XML 41 R31.htm IDEA: XBRL DOCUMENT

Note 3 - Goodwill and Intangible Assets - Future Amortization Expense of Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
2022 (remainder of year)	$ 4,366
2023	5,728
2024	5,427
2025	4,109
2026	2,368
Thereafter	3,646
Total	$ 25,644	$ 27,147

XML 42 R32.htm IDEA: XBRL DOCUMENT

Note 4 - Balance Sheet Information - Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Finished goods	$ 6,798	$ 5,646
Work in process	3,439	3,410
Raw materials	18,474	18,531
Total	$ 28,711	$ 27,587

XML 43 R33.htm IDEA: XBRL DOCUMENT

Note 4 - Balance Sheet Information - Other Current Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Compensation	$ 2,878	$ 6,048
Professional fees	396	480
Warranty costs	242	240
Customer related costs	2,058	2,265
Estimated Litigation Liability, Current	4,814	0
Accrued income taxes	141	224
Other	1,653	1,505
Total	$ 12,181	$ 10,762

XML 44 R34.htm IDEA: XBRL DOCUMENT

Note 5 - Restructuring and Other Exit Costs (Details Textual) $ in Millions	3 Months Ended
	Mar. 31, 2021 USD ($)
Selling, General and Administrative Expenses [Member]
Restructuring Charges, Total	$ 0.6

XML 45 R35.htm IDEA: XBRL DOCUMENT

Note 6 - Related Party Transactions (Details Textual) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
The Multi Channel Systems Facility and Triangle BioSystems Lease Agreements [Member]
Operating Lease, Expense	$ 0.1	$ 0.1

XML 46 R36.htm IDEA: XBRL DOCUMENT

Note 7 - Leases - Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating lease cost	$ 504	$ 517
Short-term lease cost	64	46
Sublease income	(25)	(25)
Total lease cost	$ 543	$ 538

XML 47 R37.htm IDEA: XBRL DOCUMENT

Note 7- Leases - Supplemental Cash Flow Information Related to Operating Leases (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash paid for amounts included in the measurement of lease liabilities:	$ 594	$ 611
Right-of-use assets obtained in exchange for lease obligations:	$ 39	$ 0

XML 48 R38.htm IDEA: XBRL DOCUMENT

Note 7 - Leases - Supplemental Balance Sheet Information Related to Operating Leases (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Operating lease right-of-use assets	$ 6,605	$ 6,897
Current portion, operating lease liabilities	2,151	2,142
Operating lease liabilities, long-term	6,159	6,488
Total operating lease liabilities	$ 8,310	$ 8,630
Weighted average remaining lease term (years) (Year)	6 years 6 months	6 years 8 months 12 days
Weighted average discount rate	9.30%	9.30%

XML 49 R39.htm IDEA: XBRL DOCUMENT

Note 7 - Leases - Future Minimum Lease Payments (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
2022 (remainder of year)	$ 1,611
2023	2,133
2024	1,765
2025	1,019
2026	980
Thereafter	3,871
Total lease payments	11,379
Less imputed interest	(3,069)
Total operating lease liabilities	$ 8,310	$ 8,630

XML 50 R40.htm IDEA: XBRL DOCUMENT

Note 8 - Capital Stock and Stock-based Compensation (Details Textual) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	$ 8.2
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)	2 years 2 months 12 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)	$ 5.92
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	3.5	4.5

XML 51 R41.htm IDEA: XBRL DOCUMENT

Note 8 - Capital Stock and Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details)	3 Months Ended
	Mar. 31, 2022 $ / shares shares
Opening Balance, Stock Options Outstanding (in shares) \| shares	1,404,816
Options, Outstanding, Weighted Average Exercise Price (in dollars per share) \| $ / shares	$ 3.10
Options, Granted in Period (in shares) \| shares	0
Options, Granted in Period, Weighted Average Exercise Price (in dollars per share) \| $ / shares	$ 0
Options, exercised (in shares) \| shares	(10,987)
Options, exercised, weighted average exercise price (in dollars per share) \| $ / shares	$ 2.78
Options, Cancelled / Forfeited in Period (in shares) \| shares	(3,126)
Options, Cancelled / Forfeited, Weighted Average Exercise Price (in dollars per share) \| $ / shares	$ 3.79
Opening Balance, Stock Options Outstanding (in shares) \| shares	1,390,703
Options, Outstanding, Weighted Average Exercise Price (in dollars per share) \| $ / shares	$ 3.10
Restricted Stock Units (RSUs) [Member]
Restricted Stock Units Outstanding , Balance (in shares) \| shares	1,141,164
Restricted Stock Units Outstanding , Grant Date Fair Value, Balance (in dollars per share) \| $ / shares	$ 3.57
Restricted Stock Units, Granted in Period (in shares) \| shares	518,163
Restricted Stock Units Granted , Grant Date Fair Value, Balance (in dollars per share) \| $ / shares	$ 5.52
Restricted Stock Units, Vested in Period (in shares) \| shares	(151,185)
Restricted Stock Units, Vested , Grant Date Fair Value, Balance (in dollars per share) \| $ / shares	$ 2.30
Restricted Stock Units, Cancelled / Forfeited in Period (in shares) \| shares	(12,917)
Restricted Stock Units, Cancelled/ Forfeited , Grant Date Fair Value, Balance (in dollars per share) \| $ / shares	$ 3.07
Restricted Stock Units Outstanding , Balance (in shares) \| shares	1,495,225
Restricted Stock Units Outstanding , Grant Date Fair Value, Balance (in dollars per share) \| $ / shares	$ 4.37
Market Condition Restricted Stock Units [Member]
Restricted Stock Units Outstanding , Balance (in shares) \| shares	860,155
Restricted Stock Units Outstanding , Grant Date Fair Value, Balance (in dollars per share) \| $ / shares	$ 3.13
Restricted Stock Units, Granted in Period (in shares) \| shares	205,122
Restricted Stock Units Granted , Grant Date Fair Value, Balance (in dollars per share) \| $ / shares	$ 5.92
Restricted Stock Units, Vested in Period (in shares) \| shares	0
Restricted Stock Units, Vested , Grant Date Fair Value, Balance (in dollars per share) \| $ / shares	$ 0
Restricted Stock Units, Cancelled / Forfeited in Period (in shares) \| shares	0
Restricted Stock Units, Cancelled/ Forfeited , Grant Date Fair Value, Balance (in dollars per share) \| $ / shares	$ 0
Restricted Stock Units Outstanding , Balance (in shares) \| shares	1,065,277
Restricted Stock Units Outstanding , Grant Date Fair Value, Balance (in dollars per share) \| $ / shares	$ 3.67

XML 52 R42.htm IDEA: XBRL DOCUMENT

Note 8 - Capital Stock and Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based compensation	$ 1,023	$ 968
Continuing Operations [Member] \| Cost of Sales [Member]
Share-based compensation	36	20
Continuing Operations [Member] \| Selling and Marketing Expense [Member]
Share-based compensation	154	93
Continuing Operations [Member] \| General and Administrative Expense [Member]
Share-based compensation	791	834
Continuing Operations [Member] \| Research and Development Expense [Member]
Share-based compensation	$ 42	$ 21

XML 53 R43.htm IDEA: XBRL DOCUMENT

Note 8 - Capital Stock and Stock-based Compensation - Black Scholes Assumptions (Details) - Black Scholes Option Pricing Model [Member] - Share-Based Payment Arrangement, Option [Member]	3 Months Ended
	Mar. 31, 2022
Volatility	65.10%
Risk-free interest rate	1.40%
Correlation coefficient	38.50%
Dividend yield	0.00%

XML 54 R44.htm IDEA: XBRL DOCUMENT

Note 8 - Capital Stock and Stock-based Compensation - Weighted Average Number of Shares (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Basic and diluted (in shares)	41,219	39,787
Dilutive effect of equity awards (in shares)	0	0
Diluted (in shares)	41,219	39,787

XML 55 R45.htm IDEA: XBRL DOCUMENT

Note 9 - Long-Term Debt (Details Textual) - USD ($) $ in Thousands		3 Months Ended
	Apr. 28, 2022	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 22, 2020
Debt Issuance Costs, Net, Total		$ 1,050		$ 1,120
The Credit Agreement [Member]
Debt Issuance Costs, Net, Total					$ 1,400
Debt, Weighted Average Interest Rate		3.40%
Line of Credit Facility, Interest Rate During Period		3.10%	3.30%
Debt Instrument, Quarterly Payment, Current Year			$ 500
Debt Instrument Quarterly Payment Next Eight Years			750
Debt Instrument, Quarterly Payment, Thereafter			$ 1,000
Percentage of Consolidated Excess Cash Flow			50.00%
Debt Instrument, Current Maturities, Excess Cash Flow Sweep		$ 200
The Credit Agreement [Member] \| Subsequent Event [Member]
Payments of Debt Restructuring Costs	$ 200
The Credit Agreement [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Interest Rate, State Floor Percentage		0.50%
The Credit Agreement [Member] \| London Interbank Offered Rate (LIBOR) [Member] \| Maximum [Member]
Debt Instrument, Basis Spread on Variable Rate		3.25%
The Credit Agreement [Member] \| Base Rate [Member]
Debt Instrument, Interest Rate, State Floor Percentage		1.00%
The Credit Agreement [Member] \| The ABR Loan [Member] \| Minimum [Member]
Debt Instrument, Basis Spread on Variable Rate		1.50%
The Credit Agreement [Member] \| The ABR Loan [Member] \| Maximum [Member]
Debt Instrument, Basis Spread on Variable Rate		3.00%
The Credit Agreement [Member] \| Revolving Credit Facility [Member]
Line of Credit Facility, Remaining Borrowing Capacity		$ 6,800
Term Loan [Member]
Long-term Debt, Gross		$ 37,064		$ 38,000
The LIBOR Loan and Pricing Grid Credit Agreement [Member] \| The Credit Agreement [Member] \| London Interbank Offered Rate (LIBOR) [Member] \| Minimum [Member]
Debt Instrument, Basis Spread on Variable Rate		2.00%
The Lenders [Member] \| The Credit Agreement [Member] \| Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity					25,000
The Lenders [Member] \| The Credit Agreement [Member] \| Letter of Credit [Member]
Line of Credit Facility, Maximum Borrowing Capacity					10,000
The Lenders [Member] \| The Credit Agreement [Member] \| Swingline Loan Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity					10,000
The Lenders [Member] \| Term Loan [Member] \| The Credit Agreement [Member]
Long-term Debt, Gross					$ 40,000

XML 56 R46.htm IDEA: XBRL DOCUMENT

Note 9 - Long-term Debt - Breakdown of Borrowings (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Less unamortized deferred financing costs	$ (1,050)	$ (1,120)
Total debt	48,964	48,330
Current portion of long-term debt	(3,000)	(3,515)
Current unamortized deferred financing costs	280	280
Long-term debt	46,244	45,095
Term Loan [Member]
Long-term debt, gross	37,064	38,000
Line of Credit [Member]
Long-term debt, gross	$ 12,950	$ 11,450

- Definition

Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.

+ References + Details

XML 57 R47.htm IDEA: XBRL DOCUMENT

Note 10 - Revenues (Details Textual) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Contract with Customer, Liability, Revenue Recognized	$ 0.7	$ 1.2

XML 58 R48.htm IDEA: XBRL DOCUMENT

Note 10 - Revenues - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenues	$ 28,778	$ 26,989
Instruments, Equipment, Software, and Accessories [Member]
Revenues	27,538	25,827
Service, Maintenance, and Warranty Contracts [Member]
Revenues	$ 1,240	$ 1,162

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

XML 59 R49.htm IDEA: XBRL DOCUMENT

Note 10 - Segment and Related Information - Revenue by Geographic Destination (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Total revenues	$ 28,778	$ 26,989
UNITED STATES
Total revenues	12,239	11,177
Europe [Member]
Total revenues	7,823	8,589
CHINA
Total revenues	6,733	5,538
Rest of the World [Member]
Total revenues	$ 1,983	$ 1,685

- Definition

+ References

+ Details

XML 60 R50.htm IDEA: XBRL DOCUMENT

Note 10 - Revenues - Deferred Revenue (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Deferred revenue	$ 3,956	$ 4,266
Service [Member]
Deferred revenue	1,995	1,976
Customer Advances [Member]
Deferred revenue	$ 1,961	$ 2,290

XML 61 R51.htm IDEA: XBRL DOCUMENT

Note 10 - Revenues - Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Balance, beginning of period	$ 136	$ 227
Bad debt (credit) expense	(6)	5
Charge-offs and other	6	22
Balance, end of period	$ 136	$ 254

XML 62 R52.htm IDEA: XBRL DOCUMENT

Note 11 - Income Tax (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Tax Expense (Benefit), Total	$ (138)	$ (15)
Effective Income Tax Rate Reconciliation, Percent, Total	2.00%	2.20%
Maximum [Member]
Income Tax Expense (Benefit), Total		$ (100)

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

XML 63 R53.htm IDEA: XBRL DOCUMENT

Note 13 - Subsequent Events (Details Textual) - USD ($) $ in Millions	Apr. 28, 2022	Apr. 27, 2022	Mar. 31, 2022
Subsequent Event [Member] \| The Credit Agreement [Member]
Payments of Debt Restructuring Costs	$ 0.2
Case in Suffolk Superior Court [Member]
Loss Contingency, Estimate of Possible Loss			$ 5.2
Case in Suffolk Superior Court [Member] \| Subsequent Event [Member] \| Convertible Preferred Stock [Member]
Stock Issued During Period, Value, Issued for Settlement		$ 4.0

XML 64 hboi20220331_10q_htm.xml IDEA: XBRL DOCUMENT 0001123494 2022-01-01 2022-03-31 0001123494 2022-04-29 0001123494 2022-03-31 0001123494 2021-12-31 0001123494 2021-01-01 2021-03-31 0001123494 us-gaap:CommonStockMember 2021-12-31 0001123494 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001123494 us-gaap:RetainedEarningsMember 2021-12-31 0001123494 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001123494 us-gaap:TreasuryStockMember 2021-12-31 0001123494 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001123494 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001123494 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001123494 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001123494 us-gaap:TreasuryStockMember 2022-01-01 2022-03-31 0001123494 us-gaap:CommonStockMember 2022-03-31 0001123494 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001123494 us-gaap:RetainedEarningsMember 2022-03-31 0001123494 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001123494 us-gaap:TreasuryStockMember 2022-03-31 0001123494 us-gaap:CommonStockMember 2020-12-31 0001123494 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001123494 us-gaap:RetainedEarningsMember 2020-12-31 0001123494 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001123494 us-gaap:TreasuryStockMember 2020-12-31 0001123494 2020-12-31 0001123494 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001123494 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001123494 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001123494 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001123494 us-gaap:TreasuryStockMember 2021-01-01 2021-03-31 0001123494 us-gaap:CommonStockMember 2021-03-31 0001123494 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001123494 us-gaap:RetainedEarningsMember 2021-03-31 0001123494 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001123494 us-gaap:TreasuryStockMember 2021-03-31 0001123494 2021-03-31 0001123494 hbio:DistributionAgreementscustomerRelationshipsMember 2022-01-01 2022-03-31 0001123494 hbio:DistributionAgreementscustomerRelationshipsMember 2022-03-31 0001123494 hbio:DistributionAgreementscustomerRelationshipsMember 2021-12-31 0001123494 hbio:ExistingTechnologyMember 2022-01-01 2022-03-31 0001123494 hbio:ExistingTechnologyMember 2022-03-31 0001123494 hbio:ExistingTechnologyMember 2021-12-31 0001123494 hbio:TradeNamesAndPatentsMember 2022-01-01 2022-03-31 0001123494 hbio:TradeNamesAndPatentsMember 2022-03-31 0001123494 hbio:TradeNamesAndPatentsMember 2021-12-31 0001123494 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-03-31 0001123494 hbio:TheMultiChannelSystemsFacilityAndTriangleBiosystemsLeaseAgreementsMember 2022-01-01 2022-03-31 0001123494 hbio:TheMultiChannelSystemsFacilityAndTriangleBiosystemsLeaseAgreementsMember 2021-01-01 2021-03-31 0001123494 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001123494 hbio:MarketConditionRestrictedStockUnitsMember 2021-12-31 0001123494 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-03-31 0001123494 hbio:MarketConditionRestrictedStockUnitsMember 2022-01-01 2022-03-31 0001123494 us-gaap:RestrictedStockUnitsRSUMember 2022-03-31 0001123494 hbio:MarketConditionRestrictedStockUnitsMember 2022-03-31 0001123494 us-gaap:CostOfSalesMember us-gaap:SegmentContinuingOperationsMember 2022-01-01 2022-03-31 0001123494 us-gaap:CostOfSalesMember us-gaap:SegmentContinuingOperationsMember 2021-01-01 2021-03-31 0001123494 us-gaap:SellingAndMarketingExpenseMember us-gaap:SegmentContinuingOperationsMember 2022-01-01 2022-03-31 0001123494 us-gaap:SellingAndMarketingExpenseMember us-gaap:SegmentContinuingOperationsMember 2021-01-01 2021-03-31 0001123494 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:SegmentContinuingOperationsMember 2022-01-01 2022-03-31 0001123494 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:SegmentContinuingOperationsMember 2021-01-01 2021-03-31 0001123494 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:SegmentContinuingOperationsMember 2022-01-01 2022-03-31 0001123494 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:SegmentContinuingOperationsMember 2021-01-01 2021-03-31 0001123494 us-gaap:EmployeeStockOptionMember hbio:BlackScholesOptionPricingModelMember 2022-01-01 2022-03-31 0001123494 hbio:TermLoanMember 2022-03-31 0001123494 hbio:TermLoanMember 2021-12-31 0001123494 us-gaap:LineOfCreditMember 2022-03-31 0001123494 us-gaap:LineOfCreditMember 2021-12-31 0001123494 hbio:TheCreditAgreementMember hbio:TheLendersMember hbio:TermLoanMember 2020-12-22 0001123494 us-gaap:RevolvingCreditFacilityMember hbio:TheCreditAgreementMember hbio:TheLendersMember 2020-12-22 0001123494 us-gaap:LetterOfCreditMember hbio:TheCreditAgreementMember hbio:TheLendersMember 2020-12-22 0001123494 hbio:SwinglineLoanFacilityMember hbio:TheCreditAgreementMember hbio:TheLendersMember 2020-12-22 0001123494 hbio:TheCreditAgreementMember 2020-12-22 0001123494 us-gaap:RevolvingCreditFacilityMember hbio:TheCreditAgreementMember 2022-03-31 0001123494 hbio:TheCreditAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2022-03-31 0001123494 hbio:TheCreditAgreementMember us-gaap:BaseRateMember 2022-03-31 0001123494 srt:MinimumMember hbio:TheCreditAgreementMember hbio:TheLIBORLoanAndPricingGridCreditAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2022-01-01 2022-03-31 0001123494 srt:MaximumMember hbio:TheCreditAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2022-01-01 2022-03-31 0001123494 srt:MinimumMember hbio:TheCreditAgreementMember hbio:TheABRLoanMember 2022-01-01 2022-03-31 0001123494 srt:MaximumMember hbio:TheCreditAgreementMember hbio:TheABRLoanMember 2022-01-01 2022-03-31 0001123494 hbio:TheCreditAgreementMember 2022-03-31 0001123494 hbio:TheCreditAgreementMember 2022-01-01 2022-03-31 0001123494 hbio:TheCreditAgreementMember 2021-01-01 2021-03-31 0001123494 hbio:TheCreditAgreementMember 2021-03-31 0001123494 hbio:TheCreditAgreementMember us-gaap:SubsequentEventMember 2022-04-28 2022-04-28 0001123494 hbio:InstrumentsEquipmentSoftwareAndAccessoriesMember 2022-01-01 2022-03-31 0001123494 hbio:InstrumentsEquipmentSoftwareAndAccessoriesMember 2021-01-01 2021-03-31 0001123494 hbio:ServiceMaintenanceAndWarrantyContractsMember 2022-01-01 2022-03-31 0001123494 hbio:ServiceMaintenanceAndWarrantyContractsMember 2021-01-01 2021-03-31 0001123494 country:US 2022-01-01 2022-03-31 0001123494 country:US 2021-01-01 2021-03-31 0001123494 srt:EuropeMember 2022-01-01 2022-03-31 0001123494 srt:EuropeMember 2021-01-01 2021-03-31 0001123494 country:CN 2022-01-01 2022-03-31 0001123494 country:CN 2021-01-01 2021-03-31 0001123494 hbio:RestOfTheWorldMember 2022-01-01 2022-03-31 0001123494 hbio:RestOfTheWorldMember 2021-01-01 2021-03-31 0001123494 us-gaap:ServiceMember 2022-03-31 0001123494 us-gaap:ServiceMember 2021-12-31 0001123494 hbio:CustomerAdvancesMember 2022-03-31 0001123494 hbio:CustomerAdvancesMember 2021-12-31 0001123494 srt:MaximumMember 2021-01-01 2021-03-31 0001123494 hbio:CaseInSuffolkSuperiorCourtMember 2022-03-31 0001123494 hbio:CaseInSuffolkSuperiorCourtMember us-gaap:ConvertiblePreferredStockMember us-gaap:SubsequentEventMember 2022-04-27 2022-04-27 0001123494 hbio:BlackScholesOptionPricingModelMember 2022-01-01 2022-03-31 thunderdome:item iso4217:USD iso4217:USD shares utr:Y pure 0001123494 HARVARD BIOSCIENCE INC false --12-31 Q1 2022

0.01

5000000

0.01

80000000

41241449

41142876

1500000

100000

10-Q true 2022-03-31 false 001-33957 DE 04-3306140 84 October Hill Road Holliston MA 01746 508 893-8999 Common Stock, $0.01 par value HBIO NASDAQ Yes Yes Accelerated Filer false false false 41241449

5433000

7821000

20274000

21834000

28711000

27587000

5030000

4341000

59448000

61583000

3499000

3415000

6605000

6897000

57356000

57689000

25878000

27385000

5258000

5375000

158044000

162344000

2720000

3235000

2151000

2142000

6218000

4911000

3956000

4266000

12181000

10762000

27226000

25316000

46244000

45095000

1442000

1558000

6159000

6488000

598000

486000

81669000

78943000

452000

226203000

225650000

-139554000

-132674000

-10726000

-10027000

76375000

83401000

158044000

162344000

28778000

26989000

12601000

11558000

16177000

15431000

6687000

5386000

6325000

6333000

3220000

2487000

1466000

1464000

5191000

22889000

15670000

-6712000

-239000

-384000

-411000

78000

-34000

-306000

-445000

-7018000

-684000

-138000

-15000

-6880000

-669000

-0.17

-0.02

41219000

39787000

-6880000

-669000

-699000

-1325000

-7579000

-1994000

41143000

452000

225650000

-132674000

-10027000

83401000

11000

31000

151000

64000

-0

501000

-0

501000

1023000

-6880000

-699000

41241000

452000

226203000

-139554000

-10726000

76375000

47153000

444000

232357000

-132386000

-13066000

-10668000

76681000

311000

4000

1920000

1924000

340000

108000

-0

464000

-0

464000

968000

-669000

-1325000

47696000

448000

234781000

-133055000

-14391000

-10668000

77115000

-6880000

-669000

382000

445000

1466000 1464000

70000

1023000

968000

123000 53000

-1506000

-584000

1308000

602000

466000

94000

2729000

-245000

-300000

-135000

-85000

-696000

-1986000

1037000

471000

151000

-0

150000

-471000

-301000

1500000

-0

4000000

936000

500000

-0

101000

31000

1924000

501000

464000

94000

-3141000

-25000

-97000

-2388000

-2502000

7821000

8317000

5433000

5815000

383000

458000

107000

-113000

<p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 25pt; text-align: justify; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">Basis of Presentation and Summary of Significant Accounting Policies <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 25pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">The unaudited consolidated financial statements of Harvard Bioscience, Inc. and its wholly-owned subsidiaries (collectively, “Harvard Bioscience” or the “Company”) as of March 31, 2022 and for the three months ended March 31, 2022 and 2021, have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. The December 31, 2021, consolidated balance sheet was derived from audited financial statements but does not include all disclosures required by U.S. GAAP. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021. In the opinion of management, all adjustments, which include normal recurring adjustments necessary to present a fair statement of financial position as of March 31, 2022, results of operations and comprehensive loss and cash flows for the three months ended March 31, 2022 and 2021, as applicable, have been made. The results of operations for the three months ended March 31, 2022, are not necessarily indicative of the operating results for the full fiscal year or any future periods. The accounting policies underlying the accompanying unaudited consolidated financial statements are set forth in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. There have been no material changes in the Company’s significant accounting policies during the three months ended March 31, 2022.

Risks and Uncertainties On March 11, 2020, the World Health Organization declared the outbreak of a novel coronavirus (COVID-19) as a pandemic. The COVID-19 pandemic has had a negative impact on the Company’s operations to date and the future impacts of the pandemic and any resulting economic impact are largely unknown and rapidly evolving. Since the global outbreak of COVID-19, many customers, particularly academic research institutions, have reduced laboratory work which has negatively impacted, and will continue to negatively impact, the Company’s sales. Also, countries world-wide continue to issue COVID-19 related policies in an attempt to control the pandemic. In particular, during the beginning of 2022, China implemented area-wide shutdowns in order to control the spread of COVID-19. To ensure business continuity while maintaining a safe environment for employees aligned with guidance from government and health organizations, the Company transitioned a significant portion of its workforce to work-from-home while implementing social distancing requirements and other measures to allow manufacturing and other personnel essential to production to continue work within the Company's facilities. Business travel was significantly reduced during this period. While a portion of the workforce has returned to in-office work and travel is less restricted, the Company continued to have restrictions which represent disruptions that can impact productivity including sales and marketing activities. The global supply chain has experienced significant disruptions due to electronic component and labor shortages and other macroeconomic factors which have emerged since the onset of COVID-19, leading to increased cost of freight, purchased materials, and manufacturing labor costs, while also delaying customer shipments. Accordingly, these conditions in addition to the overall impact on the global economy have negatively impacted results of operations and cash flows.

<table cellpadding="0" cellspacing="0" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;"><tbody><tr style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="vertical-align: top; width: 2%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 3. </td><td style="vertical-align: top; width: 98%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Goodwill and Intangible Assets </td></tr> </tbody></table> Goodwill The change in the carrying amount of goodwill for the three months ended March 31, 2022, were as follows: <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 60%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 22pt;"><tbody><tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 81%;"> (in thousands) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Carrying amount at December 31, 2021 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">57,689</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Effect of change in currency translation </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(333</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Carrying amount at March 31, 2022 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">57,356</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> Intangible Assets Identifiable intangible assets at March 31, 2022 and December 31, 2021 consist of the following: <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 95%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 22pt;"><tbody><tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> March 31, 2022 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, 2021 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 23%;"> (in thousands) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Average </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Accumulated </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Accumulated </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Amortizable intangible assets: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Life* </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Gross </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Amortization </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Net </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Gross </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Amortization </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Net </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Distribution agreements/customer relationships </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 8%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">7.7</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17,594</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(8,938</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8,656</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17,689</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(8,675</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">9,014</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Existing technology </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 8%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">3.9</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">38,611</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(24,786</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">13,825</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">38,707</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(23,962</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">14,745</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Trade names and patents </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 8%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">4.2</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,467</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5,304</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,163</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,496</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5,108</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,388</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 0%; padding: 0px;"> Total amortizable intangible assets </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">64,672</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(39,028</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,644</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">64,892</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(37,745</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">27,147</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Indefinite-lived intangible assets: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">234</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">238</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total intangible assets </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,878</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">27,385</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> * Weighted average life in years as of March 31, 2022 Intangible asset amortization expense was $1.5 million for each the three months ended March 31, 2022 and 2021. Estimated amortization expense of existing amortizable intangible assets for each of the five succeeding years and thereafter as of March 31, 2022, is as follows: <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 60%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 22pt;"><tbody><tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Amortization </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 79%;"> Year Ending December 31, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Expense </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> (in thousands) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2022 (remainder of year) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 18%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4,366</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2023 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5,728</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5,427</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2025 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4,109</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2026 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,368</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Thereafter </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 18%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">3,646</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 18%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">25,644</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table>

57689000

-333000

57356000

<table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 95%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 22pt;"><tbody><tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> March 31, 2022 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, 2021 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 23%;"> (in thousands) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Average </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Accumulated </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Accumulated </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Amortizable intangible assets: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Life* </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Gross </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Amortization </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Net </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Gross </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Amortization </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Net </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Distribution agreements/customer relationships </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 8%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">7.7</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17,594</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(8,938</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8,656</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17,689</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(8,675</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">9,014</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Existing technology </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 8%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">3.9</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">38,611</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(24,786</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">13,825</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">38,707</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(23,962</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">14,745</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Trade names and patents </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 8%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">4.2</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,467</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5,304</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,163</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,496</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5,108</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,388</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 0%; padding: 0px;"> Total amortizable intangible assets </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">64,672</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(39,028</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,644</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">64,892</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(37,745</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">27,147</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Indefinite-lived intangible assets: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">234</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">238</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total intangible assets </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,878</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 8%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">27,385</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table>

P7Y8M12D

17594000

8938000

8656000

17689000

8675000

9014000

P3Y10M24D

38611000

24786000

13825000

38707000

23962000

14745000

P4Y2M12D

8467000

5304000

3163000

8496000

5108000

3388000

64672000

39028000

25644000

64892000

37745000

27147000

234000

238000

25878000

27385000

1500000

4366000

5728000

5427000

4109000

2368000

3646000

25644000

6798000

5646000

3439000

3410000

18474000

18531000

28711000

27587000

<table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 60%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 22pt;"><tbody><tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 58%;"> Other Current Liabilities: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> March 31, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December 31, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> (in thousands) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2022 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2021 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Compensation </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,878</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,048</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Professional fees </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">396</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">480</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Warranty costs </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">242</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">240</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Customer related costs </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,058</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,265</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Settlement of litigation </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,814</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Accrued income taxes </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">141</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">224</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,653</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,505</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,181</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,762</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table>

2878000

6048000

396000

480000

242000

240000

2058000 2265000

4814000

141000

224000

1653000

1505000

12181000

10762000

600000

100000

504000

517000

64000

46000

25000

543000

538000

594000

611000

39000

<table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 60%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 22pt;"><tbody><tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> March 31, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December 31, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 58%;"> (in thousands) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2022 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2021 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Operating lease right-of-use assets </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,605</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,897</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Current portion, operating lease liabilities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,151</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,142</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Operating lease liabilities, long-term </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,159</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,488</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total operating lease liabilities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,310</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,630</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Weighted average remaining lease term (years) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6.5</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6.7</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Weighted average discount rate </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">9.3</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">9.3</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr> </tbody></table>

6605000

6897000

2151000

2142000

6159000

6488000

8310000

8630000

P6Y6M

P6Y8M12D

0.093

<table cellpadding="0" cellspacing="0" class="finTable" style="width: 50%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 22pt; margin-right: auto;"><tbody><tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%; border-bottom: 1px solid rgb(0, 0, 0);"> Year Ending December 31, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> (in thousands) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2022 (remainder of year) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,611</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2023 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,133</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,765</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2025 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,019</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2026 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">980</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Thereafter </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,871</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total lease payments </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">11,379</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Less imputed interest </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,069</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> ) </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total operating lease liabilities </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,310</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table>

1611000

2133000

1765000

1019000

980000

3871000

11379000

3069000

8310000

<table cellpadding="0" cellspacing="0" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;"><tbody><tr style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="vertical-align: top; width: 2%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 8. </td><td style="vertical-align: top; width: 98%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Capital Stock and Stock-Based Compensation </td></tr> </tbody></table> Stock-Based Payment Awards Stock-based awards consist of stock options, time-based restricted stock units (“RSUs”), performance-based RSU’s and shares issued under the Company’s employee stock purchase plan. Activity under the Company’s equity incentive plans for the three months ended March 31, 2022, was as follows: <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 95%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 22pt;"><tbody><tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Weighted </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Stock </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Average </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Time-Based </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Performance- </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Options </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Exercise </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> RSUs </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Grant Date </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Based RSUs </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Grant Date </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Outstanding </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Price </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Outstanding </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Fair Value </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Outstanding </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Fair Value </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 22%; padding: 0px;"> Balance at December 31, 2021 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,404,816</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3.10</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,141,164</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3.57</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">860,155</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3.13</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Granted </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">518,163</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5.52</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">205,122</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5.92</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Exercised </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(10,987</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2.78</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Vested (RSUs) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(151,185</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2.30</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Cancelled/Forfeited </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(3,126</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3.79</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(12,917</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3.07</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Balance at March 31, 2022 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1,390,703</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3.10</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1,495,225</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4.37</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1,065,277</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3.67</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> Stock-based compensation expense for the three months ended March 31, 2022 and 2021, was allocated as follows: <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 60%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 22pt;"><tbody><tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended March 31, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 58%;"> (in thousands) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2022 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2021 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Cost of revenues </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 18%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">36</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 18%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">20</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Sales and marketing expenses </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">154</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">93</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> General and administrative expenses </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">791</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">834</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Research and development expenses </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 18%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">42</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 18%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">21</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total stock-based compensation expenses </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 18%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1,023</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 18%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">968</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> As of March 31, 2022, the total compensation costs related to unvested awards not yet recognized is $8.2 million and the weighted average period over which it is expected to be recognized is approximately 2.2 years. The Company did not capitalize any stock-based compensation. The weighted average estimated fair value of the performance-based RSUs that were granted during the three months ended March 31, 2022 was $5.92 per unit. The following assumptions were used to estimate the fair value of the performance-based RSUs granted during the three months ended March 31, 2022 using a Monte-Carlo valuation simulation: <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 50%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 22pt;"><tbody><tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2022 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 77%;"> Volatility </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">65.1</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> % </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Risk-free interest rate </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1.4</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> % </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Correlation coefficient </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">38.5</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> % </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Dividend yield </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> % </td></tr> </tbody></table> Earnings (Loss) Per Share Basic earnings (loss) per share (EPS) is calculated by dividing net income (loss) by the number of weighted average shares of common stock outstanding during the period. The calculation of diluted earnings per share assumes conversion of stock options, time-based RSUs, and performance-based RSUs into common stock using the treasury method. The weighted average number of shares used to compute basic and diluted earnings per share consists of the following: <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 60%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 22pt;"><tbody><tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 0%; padding: 0px;"> Three Months Ended March 31, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 58%;"> (in thousands) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2022 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2021 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Basic </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">41,219</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">39,787</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Dilutive effect of equity awards </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 18%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 18%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Diluted </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 18%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">41,219</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 18%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">39,787</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> For the three months ended March 31, 2022, and 2021, the Company excluded from the calculations of diluted earnings per share approximately 3.5 million shares and 4.5 million shares, respectively, of weighted average shares of underlying stock-based awards as the impact of including these potential shares would be anti-dilutive.

<table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 95%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 22pt;"><tbody><tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Weighted </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Stock </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Average </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Time-Based </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Performance- </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Options </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Exercise </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> RSUs </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Grant Date </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Based RSUs </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Grant Date </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Outstanding </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Price </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Outstanding </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Fair Value </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Outstanding </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Fair Value </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 22%; padding: 0px;"> Balance at December 31, 2021 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,404,816</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3.10</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,141,164</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3.57</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">860,155</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3.13</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Granted </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">518,163</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5.52</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">205,122</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5.92</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Exercised </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(10,987</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2.78</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Vested (RSUs) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(151,185</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2.30</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Cancelled/Forfeited </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(3,126</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3.79</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(12,917</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3.07</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Balance at March 31, 2022 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1,390,703</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3.10</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1,495,225</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4.37</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1,065,277</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3.67</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table>

1404816

3.10

1141164

3.57

860155

3.13

518163

5.52

205122

5.92

10987

2.78

151185

2.30

-0

3126

3.79

12917

3.07

-0

1390703

3.10

1495225

4.37

1065277

3.67

36000

20000

154000

93000

791000

834000

42000

21000

1023000

968000

8200000

P2Y2M12D

5.92

<table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 50%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 22pt;"><tbody><tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2022 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 77%;"> Volatility </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">65.1</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> % </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Risk-free interest rate </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1.4</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> % </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Correlation coefficient </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">38.5</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> % </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Dividend yield </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 20%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> % </td></tr> </tbody></table>

0.651

0.014

0.385

41219000

39787000

41219000

39787000

3500000

4500000

<table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 60%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 22pt;"><tbody><tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> March 31, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> December 31, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 58%;"> (in thousands) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2022 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2021 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Long-term debt: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Term loan </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">37,064</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">38,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Revolving line </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">12,950</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">11,450</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Less unamortized deferred financing costs </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,050</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,120</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total debt </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">48,964</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">48,330</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Current portion of long-term debt </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(3,000</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(3,515</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 0%; padding: 0px;"> Current unamortized deferred financing costs </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">280</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">280</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Long-term debt </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">46,244</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 18%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">45,095</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table>

37064000

38000000

12950000

11450000

1050000

1120000

48964000

48330000

3000000

3515000

280000

46244000

45095000

40000000.0

25000000.0

10000000.0

1400000

6800000

0.0050 0.010

0.020

0.0325

0.015

0.030

0.034

0.031

0.033

500000 750000 1000000.0 0.50 200000

200000

27538000

25827000

1240000

1162000

28778000

26989000

12239000

11177000

7823000

8589000

6733000

5538000

1983000

1685000

28778000

26989000

1995000

1976000

1961000

2290000

3956000

4266000

700000

1200000

136000

227000

-6000

5000

-6000 -22000

136000

254000

-100000

0.020

0.022

5200000

4000000.0

200000

Weighted average life in years as of December 31, 2021

EXCEL 65 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

&UL4$L! A0#% @ &XD5.+^TTZ<4@ $(P$ !4 ( ! M:G( &AB:6\M,C R,C S,S%?;&%B+GAM;%!+ 0(4 Q0 ( !N"I%1+3M+J M"ST #5Z!0 5 " 3G% !H8FEO+3(P,C(P,S,Q7W!R92YX M;6Q02P$"% ,4 " ;@J142YG- W73 =<0P % @ %W M @$ :&)O:3(P,C(P,S,Q7S$P<2YH=&U02P4& H "@!Y @ 'M8! end